×
  • Select the area you would like to search.
  • ACTIVE INVESTIGATIONS Search for current projects using the investigator's name, institution, or keywords.
  • EXPERTS KNOWLEDGE BASE Enter keywords to search a list of questions and answers received and processed by the ADNI team.
  • ADNI PDFS Search any ADNI publication pdf by author, keyword, or PMID. Use an asterisk only to view all pdfs.

Data Dictionary

Entering terms or keywords in the Data Dictionary search above provides a definition, and entering specific terms within the data archive provides data location.

Results for "RID"
TermDefinitionCodePhaseTableCRF
USERID N/A N/A ADNI1,ADNIGO AAL N/A
USERID2 N/A N/A ADNI1,ADNIGO AAL N/A
USERID N/A N/A ADNI1,ADNIGO AALFLD N/A
USERID2 N/A N/A ADNI1,ADNIGO AALFLD N/A
USERID N/A N/A ADNI1,ADNIGO AALMETA N/A
USERID2 N/A N/A ADNI1,ADNIGO AALMETA N/A
RID Participant roster ID N/A ADNI1,ADNIGO AALMETA N/A
USERID N/A N/A ADNI1,ADNIGO AALREASON N/A
USERID2 N/A N/A ADNI1,ADNIGO AALREASON N/A
USERID N/A N/A ADNI1,ADNIGO AALTBL N/A
USERID N/A N/A ADNI1,ADNIGO AALVALUE N/A
USERID2 N/A N/A ADNI1,ADNIGO AALTBL N/A
USERID N/A N/A ADNI1,ADNIGO AALUSER N/A
USERID2 N/A N/A ADNI1,ADNIGO AALUSER N/A
USERID2 N/A N/A ADNI1,ADNIGO AALVALUE N/A
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 ADAS ADAS-Cognitive Behavior
USERID N/A N/A ADNI1,ADNIGO,ADNI2 ADAS ADAS-Cognitive Behavior
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 ADAS ADAS-Cognitive Behavior
RID Participant roster ID N/A ADNI1 ADASSCORES ADAS Sub-Scores and Total Scores
USERID N/A N/A ADNI1 ADASSCORES ADAS Sub-Scores and Total Scores
USERID2 N/A N/A ADNI1 ADASSCORES ADAS Sub-Scores and Total Scores
RID Participant roster ID N/A ADNI1 ADDCOMM Additional Comments
USERID N/A N/A ADNI1 ADDCOMM Additional Comments
USERID2 N/A N/A ADNI1 ADDCOMM Additional Comments
RID Participant roster ID -4 ADNI1 ADNIMERGE Key ADNI tables merged into one table
RID Participant roster ID N/A ADNI1,ADNIGO ADSXLIST Diagnosis and Symptoms Checklist
USERID N/A N/A ADNI1,ADNIGO ADSXLIST Diagnosis and Symptoms Checklist
USERID2 N/A N/A ADNI1,ADNIGO ADSXLIST Diagnosis and Symptoms Checklist
RID Participant roster ID N/A ADNI1 APOE ApoE Genotyping - Draw Data
USERID N/A N/A ADNI1 APOE ApoE Genotyping - Draw Data
USERID2 N/A N/A ADNI1 APOE ApoE Genotyping - Draw Data
RID Participant roster ID N/A ADNI1,ADNIGO APOERES ApoE Genotyping - Results
USERID N/A N/A ADNI1,ADNIGO APOERES ApoE Genotyping - Results
USERID2 N/A N/A ADNI1,ADNIGO APOERES ApoE Genotyping - Results
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 ARM N/A
USERID N/A N/A ADNI1,ADNIGO,ADNI2 ARM N/A
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 ARM N/A
RID Participant roster ID -4 ADNI1 AVGJACOB Average Jacobian - Temporal (Paul Thompson's Lab)
USERID N/A -4 ADNI1 AVGJACOB Average Jacobian - Temporal (Paul Thompson's Lab)
RID Participant roster ID -4 ADNI1 BACEAPPBETA Biomarkers Consortium ADNI CSF BACE activity and sAPPbeta
USERID N/A N/A ADNI1 BAINMRC Banner Alzheimer's Institute NMRC Summaries
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 BIOMARK Biomarker Samples
USERID N/A N/A ADNI1,ADNIGO,ADNI2 BIOMARK Biomarker Samples
RID Participant roster ID N/A ADNI1,ADNIGO BLCHANGE Diagnostic Summary - Baseline Changes
USERID N/A N/A ADNI1,ADNIGO BLCHANGE Diagnostic Summary - Baseline Changes
USERID2 N/A N/A ADNI1,ADNIGO BLCHANGE Diagnostic Summary - Baseline Changes
RID Participant roster ID N/A ADNI1,ADNIGO BLSCHECK Baseline Symptoms Checklist
USERID N/A N/A ADNI1,ADNIGO BLSCHECK Baseline Symptoms Checklist
USERID2 N/A N/A ADNI1,ADNIGO BLSCHECK Baseline Symptoms Checklist
USERID N/A N/A ADNI1 BSI Boundary Shift Integral Summaries (Nick Fox's lab)
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 CDR Clinical Dementia Rating
USERID N/A N/A ADNI1,ADNIGO,ADNI2 CDR Clinical Dementia Rating
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 CDR Clinical Dementia Rating
RID Participant roster ID N/A ADNI1 CELLIMORT Cells For Immortalization Speciman Collection
USERID N/A N/A ADNI1 CELLIMORT Cells For Immortalization Speciman Collection
USERID2 N/A N/A ADNI1 CELLIMORT Cells For Immortalization Speciman Collection
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 CLIREV Clinician Review
USERID N/A N/A ADNI1,ADNIGO,ADNI2 CLIREV Clinician Review
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 CLIREV Clinician Review
RID Participant roster ID N/A ADNI1,ADNIGO CSFMETH Method of CSF Collection
USERID2 N/A N/A ADNI1,ADNIGO CSFMETH Method of CSF Collection
GRID N/A N/A ADNI1,ADNIGO DATADIC N/A
RID Participant roster ID N/A ADNI1 ELIGCONF Eligibility Confirmation
USERID N/A N/A ADNI1 ELIGCONF Eligibility Confirmation
USERID2 N/A N/A ADNI1 ELIGCONF Eligibility Confirmation
RID Participant roster ID N/A ADNI1 ENROLLTR Enrollment Tracking
USERID N/A N/A ADNI1 ENROLLTR Enrollment Tracking
USERID2 N/A N/A ADNI1 ENROLLTR Enrollment Tracking
RID Participant roster ID N/A ADNI1 EXCLUSIO Exclusion Criteria
USERID N/A N/A ADNI1 EXCLUSIO Exclusion Criteria
USERID2 N/A N/A ADNI1 EXCLUSIO Exclusion Criteria
RID Participant roster ID N/A ADNI1 EXCPTLOG Inclusion/Exclusion Exceptions Log
USERID N/A N/A ADNI1 EXCPTLOG Inclusion/Exclusion Exceptions Log
USERID2 N/A N/A ADNI1 EXCPTLOG Inclusion/Exclusion Exceptions Log
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 FAQ Functional Assessment Questionnaire
USERID N/A N/A ADNI1,ADNIGO,ADNI2 FAQ Functional Assessment Questionnaire
FAQGAME 4. Playing a game of skill such as bridge or chess, working on a hobby. 0=Normal (0);1=Never did, but could do now (0);2=Never did, would have difficulty now (1);3=Has difficulty, but does by self (1);4=Requires assistance (2);5=Dependent (3) ADNI1,ADNIGO,ADNI2,ADNI3 FAQ Functional Assessment Questionnaire
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 FAQ Functional Assessment Questionnaire
RID Participant roster ID N/A ADNI1 FHQ Family History Questionnaire
USERID2 N/A N/A ADNI1 FHQ Family History Questionnaire
RID Participant roster ID N/A ADNI1 FLAIRQC FLAIR QC
USERID N/A N/A ADNI1 FORMVER N/A
USERID2 N/A N/A ADNI1 FORMVER N/A
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 GDSCALE Geriatric Depression Scale
USERID N/A N/A ADNI1,ADNIGO,ADNI2 GDSCALE Geriatric Depression Scale
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 GDSCALE Geriatric Depression Scale
RID Participant roster ID N/A ADNI1,ADNIGO HCRES Homocysteine - Results
USERID N/A N/A ADNI1,ADNIGO HCRES Homocysteine - Results
USERID2 N/A N/A ADNI1 INCLUSIO Inclusion Criteria
RID Participant roster ID -4 ADNI1 INVENTORY Inventory
USERID N/A -4 ADNI1 ISOPROSTANE Baseleine isoprostanes data. ADNI Biomarker Core laboratory
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 LABDATA Laboratory Data
RCT19 Test RCT19; Triglycerides (GPO) N/A ADNI1,ADNIGO,ADNI2 LABDATA Laboratory Data
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 LABDATA Laboratory Data
USERID N/A N/A ADNI1 LABTESTS Clinical Laboratory Tests
USERID2 N/A N/A ADNI1 LABTESTS Clinical Laboratory Tests
USERID N/A N/A ADNI1,ADNIGO LOCLAB CSF - Local Lab Results
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 MEDHIST Medical History
USERID N/A N/A ADNI1,ADNIGO,ADNI2 MEDHIST Medical History
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 MEDHIST Medical History
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 MMSE Mini Mental State Exam
USERID N/A N/A ADNI1,ADNIGO,ADNI2 MMSE Mini Mental State Exam
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 MMSE Mini Mental State Exam
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 MODHACH Modified Hachinski
USERID N/A N/A ADNI1,ADNIGO,ADNI2 MODHACH Modified Hachinski
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 MODHACH Modified Hachinski
RID Participant roster ID N/A ADNI1 MRI3META 3T MRI Scan Information
USERID N/A N/A ADNI1 MRI3META 3T MRI Scan Information
USERID2 N/A N/A ADNI1 MRI3META 3T MRI Scan Information
RID Participant roster ID N/A ADNI1 MRIB1CALIB MRI B1 Calibration
USERID N/A N/A ADNI1 MRIB1CALIB MRI B1 Calibration
USERID2 N/A N/A ADNI1 MRIB1CALIB MRI B1 Calibration
RID Participant roster ID N/A ADNI1,ADNIGO MRIMETA 1.5T MRI Scan Information
USERID N/A N/A ADNI1,ADNIGO MRIMETA 1.5T MRI Scan Information
USERID2 N/A N/A ADNI1,ADNIGO MRIMETA 1.5T MRI Scan Information
RID Participant roster ID N/A ADNI1 MRIMPPRO MRI MPRAGE Process
USERID N/A N/A ADNI1 MRIMPPRO MRI MPRAGE Process
USERID2 N/A N/A ADNI1 MRIMPPRO MRI MPRAGE Process
RID Participant roster ID N/A ADNI1 MRIMPRANK MRI MPRAGE Ranking
USERID N/A N/A ADNI1 MRIMPRANK MRI MPRAGE Ranking
USERID2 N/A N/A ADNI1 MRIMPRANK MRI MPRAGE Ranking
RID Participant roster ID N/A ADNI1,ADNIGO MRINCL1 Archive MRI Subject Inclusion
USERID N/A N/A ADNI1,ADNIGO MRINCL1 Archive MRI Subject Inclusion
USERID2 N/A N/A ADNI1,ADNIGO MRINCL1 Archive MRI Subject Inclusion
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 MRINCLUSIO MRI Subject Inclusion
USERID N/A N/A ADNI1,ADNIGO,ADNI2 MRINCLUSIO MRI Subject Inclusion
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 MRINCLUSIO MRI Subject Inclusion
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 VITALS Vital Signs
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 VITALS Vital Signs
USERID N/A N/A ADNI1,ADNIGO,ADNI2 VITALS Vital Signs
RID Participant roster ID N/A ADNI1 UWOVENT University of Western Ontario (Bartha Lab) Ventricular Volumes
USERID N/A N/A ADNI1 UWOVENT University of Western Ontario (Bartha Lab) Ventricular Volumes
RID Participant roster ID N/A ADNI1 MRIPHANTOM MRI Phantom
USERID -4 -4 ADNI1 UPENNBIOMK3 UPENN Longitudinal Biomarker Data (3 yr)
USERID -4 -4 ADNI1 UPENNBIOMK2 UPENN Longitudinal Biomarker Data
USERID N/A N/A ADNI1 UPENNBIOMK UPENN Biomarker Data
USERID2 N/A N/A ADNI1 UPENNBIOMK UPENN Biomarker Data
USERID N/A N/A ADNI1 MRIPHANTOM MRI Phantom
RID Participant roster ID N/A ADNI1 UPENNBIOMK UPENN Biomarker Data
USERID N/A -4 ADNI1 UCSFSNTVOL UCSF SNT Hippocampal Volumes
USERID2 N/A N/A ADNI1 MRIPHANTOM MRI Phantom
RID Participant roster ID N/A ADNI1 MRIPROT MRI Protocol
USERID N/A N/A ADNI1 MRIPROT MRI Protocol
USERID2 N/A N/A ADNI1 MRIPROT MRI Protocol
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 MRIQUALITY MRI Quality
USERID N/A N/A ADNI1,ADNIGO,ADNI2 MRIQUALITY MRI Quality
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 MRIQUALITY MRI Quality
RID Participant roster ID N/A ADNI1 MRIREAD MRI Clinical Read
USERID N/A N/A ADNI1 MRIREAD MRI Clinical Read
USERID2 N/A N/A ADNI1 MRIREAD MRI Clinical Read
RID Participant roster ID N/A ADNI1 MRISERIAL MRI Serial
USERID N/A N/A ADNI1 MRISERIAL MRI Serial
USERID2 N/A N/A ADNI1 MRISERIAL MRI Serial
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 NEUROBAT Neuropsychological Battery
USERID N/A N/A ADNI1,ADNIGO,ADNI2 NEUROBAT Neuropsychological Battery
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 NEUROBAT Neuropsychological Battery
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 NEUROEXM Neurological Exam
USERID N/A N/A ADNI1,ADNIGO,ADNI2 NEUROEXM Neurological Exam
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 NEUROEXM Neurological Exam
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 NPIQ Neuropsychiatric Inventory Q
USERID N/A N/A ADNI1,ADNIGO,ADNI2 NPIQ Neuropsychiatric Inventory Q
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 NPIQ Neuropsychiatric Inventory Q
RID Participant roster ID N/A ADNI1 PDXCONV Diagnostic Summary
USERID N/A N/A ADNI1 PDXCONV Diagnostic Summary
USERID2 N/A N/A ADNI1 PDXCONV Diagnostic Summary
RID Participant roster ID N/A ADNI1 PETMETA PET Scan Information
USERID N/A N/A ADNI1 PETMETA PET Scan Information
USERID2 N/A N/A ADNI1 PETMETA PET Scan Information
RID Participant roster ID N/A ADNI1 PETQC PET QC Tracking
USERID N/A N/A ADNI1 PETQC PET QC Tracking
USERID2 N/A N/A ADNI1 PETQC PET QC Tracking
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 PHYSICAL Physical Exam
USERID N/A N/A ADNI1,ADNIGO,ADNI2 PHYSICAL Physical Exam
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 PHYSICAL Physical Exam
RID Participant roster ID N/A ADNI1 PIBMETA PIB Scan Information
USERID N/A N/A ADNI1 PIBMETA PIB Scan Information
USERID2 N/A N/A ADNI1 PIBMETA PIB Scan Information
RID Participant roster ID N/A ADNI1 PIBQC PIB QC Tracking
USERID N/A N/A ADNI1 PIBQC PIB QC Tracking
USERID2 N/A N/A ADNI1 PIBQC PIB QC Tracking
RID Participant roster ID N/A ADNI1 PTDEMOG Participant Demographic Information
USERID N/A N/A ADNI1 PTDEMOG Participant Demographic Information
USERID2 N/A N/A ADNI1 PTDEMOG Participant Demographic Information
USERID N/A N/A ADNI1,ADNIGO QC N/A
USERID2 N/A N/A ADNI1,ADNIGO QC N/A
RID Participant roster ID -4 ADNI1 RBMQC Rules Based Medicine Plasma Multiplex QC Data
RID Participant roster ID N/A ADNI1 RBMRAW Rules Based Medicine Plasma Multiplex Raw Data
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 RECADV Adverse Events/Hospitalizations - Log
USERID N/A N/A ADNI1,ADNIGO,ADNI2 RECADV Adverse Events/Hospitalizations - Log
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 RECADV Adverse Events/Hospitalizations - Log
RID Participant roster ID N/A ADNI1,ADNIGO RECBLLOG Documentation of Baseline Symptoms Log
USERID N/A N/A ADNI1,ADNIGO RECBLLOG Documentation of Baseline Symptoms Log
USERID2 N/A N/A ADNI1,ADNIGO RECBLLOG Documentation of Baseline Symptoms Log
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 RECCMEDS Concurrent Medications Log
USERID N/A N/A ADNI1,ADNIGO,ADNI2 RECCMEDS Concurrent Medications Log
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 RECCMEDS Concurrent Medications Log
RID Participant roster ID N/A ADNI1 RECFHQ Family History Questionnaire Subtable
USERID N/A N/A ADNI1 RECFHQ Family History Questionnaire Subtable
USERID2 N/A N/A ADNI1 RECFHQ Family History Questionnaire Subtable
RID Participant roster ID N/A ADNI1 RECMHIST Medical History
USERID N/A N/A ADNI1 RECMHIST Medical History
USERID2 N/A N/A ADNI1 RECMHIST Medical History
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 REGISTRY Registry
USERID N/A N/A ADNI1,ADNIGO,ADNI2 REGISTRY Registry
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 REGISTRY Registry
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 ROSTER Roster
USERID N/A N/A ADNI1,ADNIGO,ADNI2 ROSTER Roster
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 ROSTER Roster
RID Participant roster ID -4 ADNI1 STROKESUM Stroke Summary
RID Participant roster ID -4 ADNI1 TOMM40 TOMM40 PolyT variable length polymorphism
RID Participant roster ID N/A ADNI1,ADNIGO,ADNI2 TREATDIS Early Discontinuation and Withdrawal
USERID N/A N/A ADNI1,ADNIGO,ADNI2 TREATDIS Early Discontinuation and Withdrawal
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 TREATDIS Early Discontinuation and Withdrawal
USERID N/A N/A ADNI1 UASPMVBM UA (Gene Alexander) MRI SPM voxel based morphometry (VBM) analysis
RID Participant roster ID N/A ADNI1 UCBPET Jagust Lab (UCB) - PET ROI analysis
USERID N/A N/A ADNI1 UCBPET Jagust Lab (UCB) - PET ROI analysis
USERID2 N/A N/A ADNI1 UCBPET Jagust Lab (UCB) - PET ROI analysis
USERID N/A -4 ADNI1 UCSFATRPHY UCSF (Colin Studholme) Regional Atrophy Rates
RID Participant roster ID N/A ADNI1 UCSFFRESFR Longitudinal FreeSurfer
USERID2 N/A N/A ADNI1 BAINMRC Banner Alzheimer's Institute NMRC Summaries
USERID2 N/A N/A ADNI1,ADNIGO,ADNI2 BIOMARK Biomarker Samples
USERID N/A N/A ADNI1,ADNIGO CSFMETH Method of CSF Collection
USERID N/A N/A ADNI1 FHQ Family History Questionnaire
USERID2 N/A N/A ADNI1,ADNIGO HCRES Homocysteine - Results
RID Participant roster ID N/A ADNI1 INCLUSIO Inclusion Criteria
USERID N/A N/A ADNI1 INCLUSIO Inclusion Criteria
USERID N/A N/A ADNI1,ADNIGO,ADNI2 LABDATA Laboratory Data
RID Participant roster ID N/A ADNI1 LABTESTS Clinical Laboratory Tests
RID Participant roster ID N/A ADNI1,ADNIGO LOCLAB CSF - Local Lab Results
USERID2 N/A N/A ADNI1,ADNIGO LOCLAB CSF - Local Lab Results
USERID N/A N/A ADNI1,ADNIGO LOGGING N/A
USERID2 N/A N/A ADNI1,ADNIGO LOGGING N/A
RID Participant roster ID N/A ADNIGO,ADNI2 ADDCOMM Visit Comments
USERID N/A N/A ADNIGO,ADNI2 ADDCOMM Visit Comments
USERID2 N/A N/A ADNIGO,ADNI2 ADDCOMM Visit Comments
RID Participant roster ID N/A ADNIGO APOE ApoE / GWAS / RNA Genotyping
USERID N/A N/A ADNIGO APOE ApoE / GWAS / RNA Genotyping
USERID2 N/A N/A ADNIGO APOE ApoE / GWAS / RNA Genotyping
RID Participant roster ID N/A ADNIGO AV45FOLLOW AV-45 24-48 Hour Follow-Up
USERID N/A N/A ADNIGO AV45FOLLOW AV-45 24-48 Hour Follow-Up
USERID2 N/A N/A ADNIGO AV45FOLLOW AV-45 24-48 Hour Follow-Up
RID Participant roster ID N/A ADNIGO AV45META AV-45 PET Scan Information
USERID N/A N/A ADNIGO AV45META AV-45 PET Scan Information
USERID2 N/A N/A ADNIGO AV45META AV-45 PET Scan Information
RID Participant roster ID N/A ADNIGO AV45QC AV-45 PET QC Tracking
USERID N/A N/A ADNIGO AV45QC AV-45 PET QC Tracking
USERID2 N/A N/A ADNIGO AV45QC AV-45 PET QC Tracking
RID Participant roster ID N/A ADNIGO AV45VITALS AV-45 Pre and Post Injection Vitals
USERID N/A N/A ADNIGO AV45VITALS AV-45 Pre and Post Injection Vitals
USERID2 N/A N/A ADNIGO AV45VITALS AV-45 Pre and Post Injection Vitals
RID Participant roster ID N/A ADNIGO,ADNI2 BACKMEDS Key Background Medications
USERID N/A N/A ADNIGO,ADNI2 BACKMEDS Key Background Medications
USERID2 N/A N/A ADNIGO,ADNI2 BACKMEDS Key Background Medications
USERID N/A N/A ADNIGO BLACKLIST N/A
USERID2 N/A N/A ADNIGO BLACKLIST N/A
RID Participant roster ID N/A ADNIGO CELLIMORT Immortalization Cell Collection
USERID N/A N/A ADNIGO CELLIMORT Immortalization Cell Collection
USERID2 N/A N/A ADNIGO CELLIMORT Immortalization Cell Collection
RID Participant roster ID N/A ADNIGO,ADNI2 CLIELG Clinician Verification
USERID N/A N/A ADNIGO,ADNI2 CLIELG Clinician Verification
USERID2 N/A N/A ADNIGO,ADNI2 CLIELG Clinician Verification
USERID2 N/A N/A ADNIGO,ADNI2 VIOLOG Protocol Deviations Log
RID Participant roster ID N/A ADNIGO,ADNI2 DXSUM Diagnostic Summary
USERID N/A N/A ADNIGO,ADNI2 DXSUM Diagnostic Summary
USERID2 N/A N/A ADNIGO,ADNI2 DXSUM Diagnostic Summary
RID Participant roster ID N/A ADNIGO,ADNI2 ECOGPT Everyday Cognition - Participant Self-Report
USERID N/A N/A ADNIGO,ADNI2 ECOGPT Everyday Cognition - Participant Self-Report
USERID2 N/A N/A ADNIGO,ADNI2 ECOGPT Everyday Cognition - Participant Self-Report
RID Participant roster ID N/A ADNIGO,ADNI2 FHQ Family History
USERID N/A N/A ADNIGO,ADNI2 FHQ Family History
USERID2 N/A N/A ADNIGO,ADNI2 FHQ Family History
RID Participant roster ID N/A ADNIGO GENSAMPLES Other Genetic Samples
USERID N/A N/A ADNIGO GENSAMPLES Other Genetic Samples
USERID2 N/A N/A ADNIGO GENSAMPLES Other Genetic Samples
USERID N/A N/A ADNIGO IMGDCM N/A
USERID2 N/A N/A ADNIGO IMGDCM N/A
USERID N/A N/A ADNIGO IMGDCMSTAT N/A
USERID2 N/A N/A ADNIGO IMGDCMSTAT N/A
USERID N/A N/A ADNIGO IMGFILE N/A
USERID2 N/A N/A ADNIGO IMGFILE N/A
RID Participant roster ID N/A ADNIGO IMGFILE N/A
USERID N/A N/A ADNIGO IMGFSTAT N/A
USERID2 N/A N/A ADNIGO IMGFSTAT N/A
USERID N/A N/A ADNIGO IMGFVERS N/A
USERID2 N/A N/A ADNIGO IMGFVERS N/A
RID Participant roster ID N/A ADNIGO,ADNI2 LABTESTS Screening Laboratory Tests
USERID N/A N/A ADNIGO,ADNI2 LABTESTS Screening Laboratory Tests
USERID2 N/A N/A ADNIGO,ADNI2 LABTESTS Screening Laboratory Tests
RID Participant roster ID N/A ADNIGO,ADNI2 MOCA MoCA
USERID N/A N/A ADNIGO,ADNI2 MOCA MoCA
USERID2 N/A N/A ADNIGO,ADNI2 MOCA MoCA
RID Participant roster ID N/A ADNIGO,ADNI2 MONELG Monitor Eligibility
USERID N/A N/A ADNIGO,ADNI2 MONELG Monitor Eligibility
USERID2 N/A N/A ADNIGO,ADNI2 MONELG Monitor Eligibility
RID Participant roster ID N/A ADNIGO MONREV Monitor Review
USERID N/A N/A ADNIGO MONREV Monitor Review
USERID2 N/A N/A ADNIGO MONREV Monitor Review
RID Participant roster ID N/A ADNIGO MRI3GOMETA 3T MRI Scan Information
USERID N/A N/A ADNIGO MRI3GOMETA 3T MRI Scan Information
USERID2 N/A N/A ADNIGO MRI3GOMETA 3T MRI Scan Information
ORDERID N/A N/A ADNIGO PACKETS N/A
RID Participant roster ID N/A ADNIGO,ADNI2 PETMETA FDG PET Scan Information
USERID N/A N/A ADNIGO,ADNI2 PETMETA FDG PET Scan Information
USERID2 N/A N/A ADNIGO,ADNI2 PETMETA FDG PET Scan Information
RID Participant roster ID N/A ADNIGO,ADNI2 PETQC FDG PET QC Tracking
USERID N/A N/A ADNIGO,ADNI2 PETQC FDG PET QC Tracking
USERID2 N/A N/A ADNIGO,ADNI2 PETQC FDG PET QC Tracking
USERID N/A N/A ADNIGO PIPECONF N/A
USERID2 N/A N/A ADNIGO PIPECONF N/A
RID Participant roster ID N/A ADNIGO,ADNI2 PTDEMOG Participant Demographics
USERID N/A N/A ADNIGO,ADNI2 PTDEMOG Participant Demographics
USERID2 N/A N/A ADNIGO,ADNI2 PTDEMOG Participant Demographics
RID Participant roster ID N/A ADNIGO,ADNI2 VIOLOG Protocol Deviations Log
RID Participant roster ID N/A ADNIGO RECADSX Diagnosis and Symptoms Log
USERID N/A N/A ADNIGO RECADSX Diagnosis and Symptoms Log
USERID2 N/A N/A ADNIGO RECADSX Diagnosis and Symptoms Log
RID Participant roster ID N/A ADNIGO,ADNI2 RECFHQ Family History Siblings Log
USERID N/A N/A ADNIGO,ADNI2 RECFHQ Family History Siblings Log
USERID2 N/A N/A ADNIGO,ADNI2 RECFHQ Family History Siblings Log
RID Participant roster ID N/A ADNIGO,ADNI2 RECMHIST Medical History Details Log
USERID N/A N/A ADNIGO,ADNI2 RECMHIST Medical History Details Log
USERID2 N/A N/A ADNIGO,ADNI2 RECMHIST Medical History Details Log
USERID N/A N/A ADNIGO,ADNI2 VIOLOG Protocol Deviations Log
RID Participant roster ID N/A ADNI2 GENETIC Genetic Sample Collection
RID Participant roster ID N/A ADNI2 BLCHANGE Diagnostic Summary Clinical Status
RID Participant roster ID N/A ADNI2 AV45VITALS Florbetapir F18 Pre and Post Injection Vitals
RID Participant roster ID N/A ADNI2 AV45FOLLOW Florbetapir F18 24-48 Hour Follow-Up
RID Participant roster ID N/A ADNI2 NPSTATUS Neuropathology Status
RID Participant roster ID N/A ADNI2 NPI Neuropsychiatric Inventory
RID Participant roster ID N/A ADNI2 RECBLLOG Pre-Existing Symptoms Log
RID Participant roster ID N/A ADNI2 AV45META Florbetapir F18 PET Scan Information
NPIE5 5. Does {P} avoid certain places or situations that make him.her more nervous such as riding in the car, meeting with friends, or being in crowds? 1=Yes; 0=No ADNI2 NPI Neuropsychiatric Inventory
RID Participant roster ID N/A ADNI2 RORR Return of Research Results
USERID N/A N/A ADNI2 RORR Return of Research Results
USERID2 N/A N/A ADNI2 AECHECK Adverse Event Checklist
USERID N/A N/A ADNI2 AECHECK Adverse Event Checklist
RID Participant roster ID N/A ADNI2 CCI Cognitive Change Index
USERID N/A N/A ADNI2 CCI Cognitive Change Index
RID Participant roster ID N/A ADNI2 BLSCHECK Pre-Existing Symptoms Checklist
RID Participant roster ID N/A ADNI2 AV45QC Florbetapir F18 PET QC Tracking
RID Participant roster ID N/A ADNI2 ECOGSP Everyday Cognition - Study Partner Report
RID Participant roster ID N/A ADNI2 MRIMETA MRI Scan Information
USERID2 N/A N/A ADNI2 RORR Return of Research Results
USERID2 N/A N/A ADNI2 CCI Cognitive Change Index
USERID N/A N/A ADNI2 AV45META Florbetapir F18 PET Scan Information
USERID N/A N/A ADNI2 AV45QC Florbetapir F18 PET QC Tracking
USERID N/A N/A ADNI2 AV45VITALS Florbetapir F18 Pre and Post Injection Vitals
USERID N/A N/A ADNI2 AV45FOLLOW Florbetapir F18 24-48 Hour Follow-Up
USERID N/A N/A ADNI2 MRIMETA MRI Scan Information
USERID N/A N/A ADNI2 GENETIC Genetic Sample Collection
USERID N/A N/A ADNI2 RECBLLOG Pre-Existing Symptoms Log
USERID N/A N/A ADNI2 NPSTATUS Neuropathology Status
USERID N/A N/A ADNI2 BLSCHECK Pre-Existing Symptoms Checklist
USERID N/A N/A ADNI2 NPI Neuropsychiatric Inventory
USERID N/A N/A ADNI2 BLCHANGE Diagnostic Summary Clinical Status
USERID N/A N/A ADNI2 ECOGSP Everyday Cognition - Study Partner Report
USERID2 N/A N/A ADNI2 NPSTATUS Neuropathology Status
USERID2 N/A N/A ADNI2 ECOGSP Everyday Cognition - Study Partner Report
USERID2 N/A N/A ADNI2 MRIMETA MRI Scan Information
USERID2 N/A N/A ADNI2 AV45FOLLOW Florbetapir F18 24-48 Hour Follow-Up
USERID2 N/A N/A ADNI2 AV45META Florbetapir F18 PET Scan Information
USERID2 N/A N/A ADNI2 AV45QC Florbetapir F18 PET QC Tracking
USERID2 N/A N/A ADNI2 AV45VITALS Florbetapir F18 Pre and Post Injection Vitals
USERID2 N/A N/A ADNI2 BLCHANGE Diagnostic Summary Clinical Status
USERID2 N/A N/A ADNI2 GENETIC Genetic Sample Collection
USERID2 N/A N/A ADNI2 BLSCHECK Pre-Existing Symptoms Checklist
USERID2 N/A N/A ADNI2 RECBLLOG Pre-Existing Symptoms Log
USERID2 N/A N/A ADNI2 NPI Neuropsychiatric Inventory
RID Participant roster ID N/A ADNI2 AECHECK Adverse Event Checklist
RID Participant roster ID N/A ADNI2 TAUMETA Tau AV-1451 PET Scan Information
USERID N/A N/A ADNI2 TAUMETA Tau AV-1451 PET Scan Information
USERID2 N/A N/A ADNI2 TAUMETA Tau AV-1451 PET Scan Information
RID Participant roster ID N/A ADNI2 TAUPHONE Tau AV-1451 Follow-up Phone Contact
USERID N/A N/A ADNI2 TAUPHONE Tau AV-1451 Follow-up Phone Contact
USERID2 N/A N/A ADNI2 TAUPHONE Tau AV-1451 Follow-up Phone Contact
RID Participant roster ID N/A ADNI2 TAUQC Tau AV-1451 PET QC
USERID N/A N/A ADNI2 TAUQC Tau AV-1451 PET QC
USERID2 N/A N/A ADNI2 TAUQC Tau AV-1451 PET QC
RID Participant roster ID N/A ADNI2 CBBCOMP Cogstate Brief Battery
USERID N/A N/A ADNI2 CBBCOMP Cogstate Brief Battery
USERID2 N/A N/A ADNI2 CBBCOMP Cogstate Brief Battery
RID Participant roster ID N/A ADNI2 ECG ECG
USERID N/A N/A ADNI2 ECG ECG
USERID2 N/A N/A ADNI2 ECG ECG
RID Participant roster ID N/A ADNI2 OTELGTAU Tau AV-1451 PET Eligibility
USERID N/A N/A ADNI2 OTELGTAU Tau AV-1451 PET Eligibility
USERID2 N/A N/A ADNI2 OTELGTAU Tau AV-1451 PET Eligibility
RID Participant roster ID N/A ADNI2 TRANSFER Participant Transfers
USERID N/A N/A ADNI2 TRANSFER Participant Transfers
USERID2 N/A N/A ADNI2 TRANSFER Participant Transfers
RID N/A N/A ADNI3 ADAS ADAS-Cognitive Behavior
RID N/A N/A ADNI3 ADDCOMM Visit Comments
RID N/A N/A ADNI3 AMYMETA Amyloid PET Scan Information
RID N/A N/A ADNI3 AMYQC Amyloid PET QC
RID N/A N/A ADNI3 BACKMEDS Key Background Medications
RID N/A N/A ADNI3 BHR Brain Health Registry
RID N/A N/A ADNI3 BIOMARK Biomarker Samples
RID N/A N/A ADNI3 BIOMARKQC Biomarker Samples Tracking and QC
RID N/A N/A ADNI3 BLCHANGE Diagnostic Summary Clinical Status
RID N/A N/A ADNI3 CBBCOMP Cogstate Brief Battery
RID N/A N/A ADNI3 CCI Cognitive Change Index
RID N/A N/A ADNI3 CDR Clinical Dementia Rating
RID N/A N/A ADNI3 CLIELG Clinician Verification
RID N/A N/A ADNI3 CONSENTS Consent Tracking
MRIDET Reason for nonconsent: N/A ADNI3 CONSENTS Consent Tracking
RID N/A N/A ADNI3 DXSUM Diagnostic Summary
RID N/A N/A ADNI3 DEVLOG Protocol Deviations Log
RID N/A N/A ADNI3 ECOGPT Everyday Cognition - Participant Self-Report
RID N/A N/A ADNI3 ECOGSP Everyday Cognition - Study Partner Report
RID N/A N/A ADNI3 FAMHXPAR Family History - Parents
RID N/A N/A ADNI3 FAMHXSIB Family History - Sibling Log
RID N/A N/A ADNI3 FAQ Functional Assessment Questionnaire
RID N/A N/A ADNI3 FCI Financial Capacity Instrument Short Form (FCI-SF)
RID N/A N/A ADNI3 GDSCALE Geriatric Depression Scale
RID N/A N/A ADNI3 GENETIC Genetic Sample Collection
RID N/A N/A ADNI3 GUID Global Unique Identifier (GUID)
RID N/A N/A ADNI3 LABTESTS Screening Laboratory Tests
RID N/A N/A ADNI3 LOCLAB CSF - Local Lab Results
RID N/A N/A ADNI3 MMSE Mini Mental State Exam (MMSE)
RID N/A N/A ADNI3 MOCA MoCA
RID N/A N/A ADNI3 MODHACH Modified Hachinski
RID N/A N/A ADNI3 MONELG Monitor Eligibility
RID N/A N/A ADNI3 MONREV Monitor Review
RID N/A N/A ADNI3 MRIMETA MRI Scan Information
RID N/A N/A ADNI3 NEUROBAT Neuropsychological Battery
RID N/A N/A ADNI3 NEUROEXM Neurological Exam
NPIE5 5. Does {P} avoid certain places or situations that make him.her more nervous such as riding in the car, meeting with friends, or being in crowds? 0=No;1=Yes ADNI3 NPI Neuropsychiatric Inventory
RID N/A N/A ADNI3 INITHEALTH Initial Health Assessment
RID N/A N/A ADNI3 NPIQ Neuropsychiatric Inventory Q
RID N/A N/A ADNI3 NPSTATUS Neuropathology Status
RID N/A N/A ADNI3 OTDISC Other Discontinuations and Withdrawals
RID N/A N/A ADNI3 PETMETA FDG PET Scan Information
RID N/A N/A ADNI3 PETQC FDG PET QC
RID N/A N/A ADNI3 PHYSICAL Physical Exam
RID N/A N/A ADNI3 PTDEMOG Participant Demographics
RID N/A N/A ADNI3 REGISTRY Registry
RID N/A N/A ADNI3 RORR Return of Research Results
RID N/A N/A ADNI3 ROSTER Roster
RID N/A N/A ADNI3 SOURCEUP Source Doc Upload
RID N/A N/A ADNI3 SPCONSENT Study Partner Consent
RID N/A N/A ADNI3 SPINFO Study Partner Information
RID N/A N/A ADNI3 STUDYSUM Study Visits Summary
RID N/A N/A ADNI3 SUBJECT Participant Registration
RID N/A N/A ADNI3 TAUMETA Tau AV-1451 PET Scan Information
RID N/A N/A ADNI3 TAUQC Tau AV-1451 PET QC
RID N/A N/A ADNI3 TRANSFER Participant Transfers
RID N/A N/A ADNI3 VITALS Vital Signs
RID N/A N/A ADNI3 NPI Neuropsychiatric Inventory
RID N/A N/A ADNI3 RECCMEDS Concurrent Medications Log
RID N/A N/A ADNI3 STUDIES Treatment Trials
RID N/A N/A ADNI3 ADVERSE Adverse Events Log
RID N/A N/A ADNI3 ANTIAMYTX Anti-Amyloid Treatment Information
RID Participant roster ID -4 ADNI3 CBBRESULTS Cogstate Battery Results
RID Participant roster ID N/A ADNI3 EMBICDCB Embic Corporation – Digital Cognitive Biomarkers
RID Participant roster ID -4 N/A ADMCBARCELONAPURINE AD Metabolomics Consortium Barcelona Purines
RID Participant roster ID -4 N/A ADMCBA AD Metabolomics Consortium Bile Acids
RID Participant roster ID -4 N/A ADMCDUKEP180FIAADNI2GO ADMC Duke p180 Flow Injection Analysis [ADNI GO,2]
RID Participant roster ID. NOTE: 9999999 denotes pooled sample. -4 N/A ADMCDUKEP180FIA AD Metabolomics Consortium Duke Biocrates P180 Kit Flow injection analysis
RID Participant roster ID -4 N/A ADMCDUKEP180UPLCADNI2GO ADMC Duke p180 Ultra Performance Liquid Chromatography [ADNI GO,2]
RID Participant roster ID. NOTE: 9999999 denotes pooled sample. -4 N/A ADMCDUKEP180UPLC AD Metabolomics Consortium Duke Biocrates P180 Kit Ultra Performance Liquid Chromatography
PSEUDO.URIDINE -4 -4 N/A ADMCGCTOF ADMC Metabolomic Analysis by Gas chromatography time of flight mass spectrometry (GCTOF) Data [ADNI1]
RID Participant roster ID -4 N/A ADMCGCTOF ADMC Metabolomic Analysis by Gas chromatography time of flight mass spectrometry (GCTOF) Data [ADNI1]
URIDINE -4 -4 N/A ADMCGCTOF ADMC Metabolomic Analysis by Gas chromatography time of flight mass spectrometry (GCTOF) Data [ADNI1]
C13_0 Tridecanoic acid -4 N/A ADMCGUTMETABOLITESLONG ADMC U Hawaii UPLC-MS/MS Gut Metabolites Serum Longitudinal
RID Participant roster ID -4 N/A ADMCGUTMETABOLITESLONG ADMC U Hawaii UPLC-MS/MS Gut Metabolites Serum Longitudinal
RID Participant roster ID -4 N/A ADMCHIVALMETAB Targeted UHPLC-MS analysis of High-Value Metabolites in Serum Samples
RID Participant roster ID -4 N/A ADMCLIPIDOMICSMEIKLELABLONG ADMC Lipidomics Meikle Lab Longitudinal Data Matrix
RID Participant roster ID -4 N/A ADMCM2OVEBA ADMC M2OVE-AD ADNIGO-2 Bile Acids
RID Participant roster ID -4 N/A ADMCPDINESIPCISRATIOS AD Metabolomics Consortium Phenomenome Phosphatidylcholine (PtdCho), Lysophosphatidylcholine (LPtdCho) Flow Injection Negative Ionization LC-MS/MS Internal Standard Ratios
RID Participant roster ID -4 N/A ADMCPDIPEISRATIOS AD Metabolomics Consortium Phenomenome Phosphatidylethanolamine (PtdEtn), Plasmenylethanolamine (PlsEtn) Flow Injection LC-MS/MS Internal Standard Ratios
RID Participant roster ID -4 N/A ADMCPDIPEPEAKHEIGHTS AD Metabolomics Consortium Phenomenome Phosphatidylethanolamine (PtdEtn), Plasmenylethanolamine (PlsEtn) Flow Injection LC-MS/MS Internal Standard Ratios
RID Participant roster ID -4 N/A ADMCPDIPESIPCISRATIOS AD Metabolomics Consortium Phenomenome Phosphatidylcholine (PtdCho), Lysophosphatidylcholine (LPtdCho), Sphingomyeline (SM) Flow Injection Positive Ionization LC-MS/MS Internal Standard Ratios
HDL_TG Triglycerides in HDL N/A N/A ADNINIGHTINGALELONG ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites Longitudinal
IDL_TG Triglycerides in IDL N/A N/A ADNINIGHTINGALELONG ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites Longitudinal
LDL_TG Triglycerides in LDL N/A N/A ADNINIGHTINGALELONG ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites Longitudinal
L_HDL_TG Triglycerides in large HDL N/A N/A ADNINIGHTINGALELONG ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites Longitudinal
L_LDL_TG Triglycerides in large LDL N/A N/A ADNINIGHTINGALELONG ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites Longitudinal
L_VLDL_TG Triglycerides in large VLDL N/A N/A ADNINIGHTINGALELONG ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites Longitudinal
M_HDL_TG Triglycerides in medium HDL N/A N/A ADNINIGHTINGALELONG ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites Longitudinal
M_LDL_TG Triglycerides in medium LDL N/A N/A ADNINIGHTINGALELONG ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites Longitudinal
M_VLDL_TG Triglycerides in medium VLDL N/A N/A ADNINIGHTINGALELONG ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites Longitudinal
POLYSACCHARIDES -4 -4 N/A ADNINIGHTINGALELONG ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites Longitudinal
RID Participant roster ID -4 N/A ADNINIGHTINGALELONG ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites Longitudinal
S_HDL_TG Triglycerides in small HDL N/A N/A ADNINIGHTINGALELONG ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites Longitudinal
S_LDL_TG Triglycerides in small LDL N/A N/A ADNINIGHTINGALELONG ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites Longitudinal
S_VLDL_TG Triglycerides in small VLDL N/A N/A ADNINIGHTINGALELONG ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites Longitudinal
VLDL_TG Triglycerides in VLDL N/A N/A ADNINIGHTINGALELONG ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites Longitudinal
XL_HDL_TG Triglycerides in very large HDL N/A N/A ADNINIGHTINGALELONG ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites Longitudinal
XL_VLDL_TG Triglycerides in very large VLDL N/A N/A ADNINIGHTINGALELONG ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites Longitudinal
XS_VLDL_TG Triglycerides in very small VLDL N/A N/A ADNINIGHTINGALELONG ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites Longitudinal
XXL_VLDL_TG Triglycerides in chylomicrons and extremely large VLDL N/A N/A ADNINIGHTINGALELONG ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites Longitudinal
RID Participant roster ID -4 N/A ADRC_EMORY_DDE DDE Analysis Summary
RID Participant roster ID -4 N/A AGROCAMPUS Institut Agro-ecole interne Agrocampus Ouest lipids in red blood cells
RID Participant roster ID -4 N/A ALIQUOT_LIST Aliquot count in the LDMS database
RID Participant roster ID -4 N/A BAIMRINMRC Banner Alzheimer's Institute MRI NMRC Summaries
RID N/A N/A N/A BAINMRC Banner Alzheimer's Institute NMRC Summaries
RID Participant roster ID N/A N/A BAIPETNMRCAV45 Banner Alzheimer's Institute PET NMRC AV45 Summaries
RID Participant roster ID N/A N/A BAIPETNMRCFDG Banner Alzheimer's Institute PET NMRC FDG Summaries
RID Participant roster ID N/A N/A BAIPETNMRCFTP Banner Alzheimer's Institute PET NMRC Flortaucipir (F-AV1451) Summaries
RID Participant roster ID N/A N/A BAIPETNMRC Banner Alzheimer's Institute PET NMRC Summaries
RID Participant roster ID -4 N/A BATEMANLAB Bateman Lab Plasma Abeta42/Abeta40 Ratio as a Predictor of Brain Amyloidosis
RID Participant roster ID -4 N/A BLENNOWCSFNFL Blennow Lab ADNI1 CSF NFL
RID Participant roster ID N/A N/A BLENNOWCSFNG Blennow Lab ADNI1 CSF Ng
RID Participant roster ID N/A N/A BLENNOWPLASMANFLLONG Blennow Lab ADNI1-2 Plasma neurofilament light (NFL) longitudinal
RID Participant roster ID -4 N/A BLENNOWPLASMANFL Blennow Lab ADNI1 Plasma neurofilament light (NFL)
RID Participant roster ID -4 N/A BLENNOWPLASMATAU Blennow Lab ADNI1 Plasma Tau
RID Participant roster ID -4 N/A BLENNOW_LAB_CSF_GAP_43 Blennow Lab CSF GAP 43
RID N/A N/A N/A BSI Boundary Shift Integral Summaries (Nick Fox's lab)
RID N/A -4 N/A CONVERSIONS Conversions Confirmed by Conversion Committee
RID Participant roster ID -4 N/A CSFALPHASYN CSF Alpha-synuclein, Jing Zhang Lab, University of Washington
RID Participant roster ID -4 N/A CSFC3FH CSF Complement 3 & Factor H, Jing Zhang Lab, University of Washington
RID Participant roster ID -4 N/A CSFMRM Biomarkers Consortium CSF Proteomics MRM data set
RID Participant roster ID -4 N/A DESIKANLAB Desikan Lab Polygenic Hazard Score (PHS)
RID Patient ID -4 N/A DIADEM -4
RID Participant roster ID -4 N/A DTIROI DTI ROI summary measures
RID Participant roster ID -4 N/A DTIROI_MEAN_V2 USC - DTI ROI Summary Measures v2 (Mean)
RID Participant roster ID -4 N/A DTIROI_ROBUSTMEAN_V2 USC - DTI ROI Summary Measures v2 (Robust Mean)
RID Participant roster ID -4 N/A DTIROI_V1 USC - DTI ROI Summary Measures v1
RID Participant roster ID. RID 999999 indicates pooled or other sample not associated with any ADNI participant. -4 N/A EMORY_PEPTIDERATIOS Emory targeted proteomics assay
RID Participant roster ID -4 N/A EUROIMMUN EUROIMMUN CSF Beta-Amyloid
RID Participant roster ID -4 N/A FAGANLAB Fagan lab summaries
RID Participant roster ID -4 N/A FOXLABBSI Fox Lab BSI measures
RID Participant roster ID -4 N/A FUJIREBIOABETA Fujirebio Beta-Amyloid Ratio
RID Participant roster ID -4 N/A HAASS_WASHU_LAB Haass and Wash U lab summaries
RID Participant roster ID -4 N/A HULAB ADNI Data Hu Lab
RID N/A N/A N/A ISOPROSTANE Baseleine isoprostanes data. ADNI Biomarker Core laboratory
RID Participant roster ID ADNI code N/A UCD_ADNI1_WMH Univerity of California Davis White Matter Hyperintensity Volumes (ADNI1)
RID N/A N/A N/A ITEM Item Level Data
RID Participant roster ID -4 N/A LIPIDOMICSDATABASE_MEIKLELAB ADMC Lipidomics Meikle Lab Baseline Data Matrix [ADNI1]
RID Participant roster ID -4 N/A ADNI1LIPIDOMICSRADER Rader Lab ADNI 1 Lipids CAD ALZ
RID Participant roster ID -4 N/A MESOSCALE Meso Scale Diagnostics Analysis of Residual CSF Samples
RID Participant roster ID -4 N/A MRI_INFARCTS MRI Infarcts
RID Participant roster ID -4 N/A NEUROPATH NACC Neuropathology Data Form
HDL.TG Triglycerides in HDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
IDL.TG Triglycerides in IDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
IDL.TG_. Triglycerides to total lipids ratio in IDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
L.HDL.TG Triglycerides in large HDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
L.HDL.TG_. Triglycerides to total lipids ratio in large HDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
L.LDL.TG Triglycerides in large LDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
L.LDL.TG_. Triglycerides to total lipids ratio in large LDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
L.VLDL.TG Triglycerides in large VLDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
L.VLDL.TG_. Triglycerides to total lipids ratio in large VLDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
LDL.TG Triglycerides in LDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
M.HDL.TG Triglycerides in medium HDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
M.HDL.TG_. Triglycerides to total lipids ratio in medium HDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
M.LDL.TG Triglycerides in medium LDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
M.LDL.TG_. Triglycerides to total lipids ratio in medium LDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
M.VLDL.TG Triglycerides in medium VLDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
M.VLDL.TG_. Triglycerides to total lipids ratio in medium VLDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
RID Participant roster ID -4 N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
S.HDL.TG Triglycerides in small HDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
S.HDL.TG_. Triglycerides to total lipids ratio in small HDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
S.LDL.TG Triglycerides in small LDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
S.LDL.TG_. Triglycerides to total lipids ratio in small LDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
S.VLDL.TG Triglycerides in small VLDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
S.VLDL.TG_. Triglycerides to total lipids ratio in small VLDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
SERUM.TG Serum total triglycerides N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
TG.PG Ratio of triglycerides to phosphoglycerides N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
TOTPG Total phosphoglycerides N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
VLDL.TG Triglycerides in VLDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
XL.HDL.TG Triglycerides in very large HDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
XL.HDL.TG_. Triglycerides to total lipids ratio in very large HDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
XL.VLDL.TG Triglycerides in very large VLDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
XL.VLDL.TG_. Triglycerides to total lipids ratio in very large VLDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
XS.VLDL.TG Triglycerides in very small VLDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
XS.VLDL.TG_. Triglycerides to total lipids ratio in very small VLDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
XXL.VLDL.TG Triglycerides in chylomicrons and extremely large VLDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
XXL.VLDL.TG_. Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL N/A N/A ADNINIGHTINGALE ADMC Nightingale Platform NMR Analysis of Lipoproteins and Metabolites [ADNI 1, GO, 2]
HDL_TG Triglycerides in HDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
HIGH_LACTATE Low glucose is tagged since the physiological concentration is commonly well controlled, particularly in the low concentration end. However, glucose is metabolised to pyruvate and lactate if the blood sample is kept with the cells during the sample collection process, in particular at room temperature but also to some extent at fridge temperature. The low glucose tag thus commonly reflects extended time periods prior to preparation to serum/plasma. As a result of the glycolysis, high lactate and/or high pyruvate is commonly observed along with low glucose levels. -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
HIGH_PYRUVATE Low glucose is tagged since the physiological concentration is commonly well controlled, particularly in the low concentration end. However, glucose is metabolised to pyruvate and lactate if the blood sample is kept with the cells during the sample collection process, in particular at room temperature but also to some extent at fridge temperature. The low glucose tag thus commonly reflects extended time periods prior to preparation to serum/plasma. As a result of the glycolysis, high lactate and/or high pyruvate is commonly observed along with low glucose levels. -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
IDL_TG Triglycerides in IDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
IDL_TG_PCT Triglycerides to total lipids ratio in IDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
LDL_TG Triglycerides in LDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
LOW_GLUCOSE Low glucose is tagged since the physiological concentration is commonly well controlled, particularly in the low concentration end. However, glucose is metabolised to pyruvate and lactate if the blood sample is kept with the cells during the sample collection process, in particular at room temperature but also to some extent at fridge temperature. The low glucose tag thus commonly reflects extended time periods prior to preparation to serum/plasma. As a result of the glycolysis, high lactate and/or high pyruvate is commonly observed along with low glucose levels. -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
L_HDL_TG Triglycerides in large HDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
L_HDL_TG_PCT Triglycerides to total lipids ratio in large HDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
L_LDL_TG Triglycerides in large LDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
L_LDL_TG_PCT Triglycerides to total lipids ratio in large LDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
L_VLDL_TG Triglycerides in large VLDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
L_VLDL_TG_PCT Triglycerides to total lipids ratio in large VLDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
M_HDL_TG Triglycerides in medium HDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
M_HDL_TG_PCT Triglycerides to total lipids ratio in medium HDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
M_LDL_TG Triglycerides in medium LDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
M_LDL_TG_PCT Triglycerides to total lipids ratio in medium LDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
M_VLDL_TG Triglycerides in medium VLDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
M_VLDL_TG_PCT Triglycerides to total lipids ratio in medium VLDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
PHOSPHOGLYC Phosphoglycerides -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
POLYSACCHARIDES Polysaccharide or some other type of carbohydrate signals detected. Most commonly observed along with other signs of suboptimal sample quality, but may also indicate presence of heparin. In higher concentrations, this compound prohibits the quantification of creatinine, and therefore the sample has been flagged with a "TAG", and no concentration has been provided for the sample. In lower concentrations, it may interfere with the reliable quantification of creatinine and result in artificially distorted creatinine levels. We recommend caution when interpreting absolute creatinine concentrations. -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
RID Participant roster ID -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
S_HDL_TG Triglycerides in small HDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
S_HDL_TG_PCT Triglycerides to total lipids ratio in small HDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
S_LDL_TG Triglycerides in small LDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
S_LDL_TG_PCT Triglycerides to total lipids ratio in small LDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
S_VLDL_TG Triglycerides in small VLDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
S_VLDL_TG_PCT Triglycerides to total lipids ratio in small VLDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
TG_BY_PG Ratio of triglycerides to phosphoglycerides -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
TOTAL_TG Total triglycerides -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
VLDL_TG Triglycerides in VLDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
XL_HDL_TG Triglycerides in very large HDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
XL_HDL_TG_PCT Triglycerides to total lipids ratio in very large HDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
XL_VLDL_TG Triglycerides in very large VLDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
XL_VLDL_TG_PCT Triglycerides to total lipids ratio in very large VLDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
XS_VLDL_TG Triglycerides in very small VLDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
XS_VLDL_TG_PCT Triglycerides to total lipids ratio in very small VLDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
XXL_VLDL_TG Triglycerides in chylomicrons and extremely large VLDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
XXL_VLDL_TG_PCT Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL -4 N/A ADNINIGHTINGALE2 ADMC Nightingale Platform NMR Post-Unblinding Re-Analysis of Lipoproteins and Metabolites
RID Participant ID N/A N/A NYUFDGHIP NYU FDG-PET Hippocampus (pons normalized)
RID -4 N/A N/A PIBPETSUVR U Pitt PIB PET Analysis
MRIDATE MRI date N/A N/A PICSLASHS ASHS volume data
RID Participant roster ID N/A N/A PICSLASHS ASHS volume data
RID Participant roster ID -4 N/A PLASMAABETA ABeta40 and ABeta42 quantification in plasma using ABtest40 and ABtest42
RID Participant roster ID -4 N/A PLASMA_ABETA_PROJECT_ADX_VUMC FNIH Biomarkers Consortium Plasma Abeta Project: ADx VUmc
RID Participant roster ID -4 N/A PLASMA_ABETA_PROJECT_QUANTERIX FNIH Biomarkers Consortium Plasma Abeta Project: Quanterix
RID Participant roster ID -4 N/A PLASMA_ABETA_PROJECT_ROCHE FNIH Biomarkers Consortium Plasma Abeta Project: Roche
RID Participant roster ID -4 N/A PLASMA_ABETA_PROJECT_SHIMADZU FNIH Biomarkers Consortium Plasma Abeta Project: Shimadzu
RID Participant roster ID -4 N/A PLASMA_ABETA_PROJECT_U_OF_GOTHENBURG FNIH Biomarkers Consortium Plasma Abeta Project: U of Gothenburg
RID Participant roster ID -4 N/A PLASMA_ABETA_PROJECT_WASH_U FNIH Biomarkers Consortium Plasma Abeta Project: Wash U
RID N/A N/A N/A REDOX Redox Reactive Reagents LLC ADNI R-RAA ELISA
RID Participant roster ID -4 N/A RESIDUAL_ALIQUOT_LIST Residual aliquot count in the LDMS database
RID Participant roster ID -4 N/A TBM Paul Thompson's Lab, Imaging Genetics Center (IGC), University of Southern California - Cross-sectional and longitudinal tensor-based morphometry Versions 2.0 and 2.1
RID Participant ID N/A N/A TCV Total Cranial Vault Segmentation
RID Participant roster ID -4 N/A TS_RATIO_ADJ ADNI Telomere length / Single copy gene (T/S) ratio of DNA from blood, adjusted for confounders
RID N/A N/A N/A UASPMVBM UA (Gene Alexander) MRI SPM voxel based morphometry (VBM) analysis
RID Participant roster ID -4 N/A UCBERKELEYAV1451_8MM UC Berkeley - AV1451 analysis
RID Participant roster ID -4 N/A UCBERKELEYAV1451_PVC_8MM UC Berkeley - AV1451 PVC analysis
StudyPartnerID Unique identifier for study partners N/A N/A SP_INITIAL CogState Brief Battery Report
StudyPartnerID Unique identifier for study partners N/A N/A BHR_SP_STUDY_CONFIRMATION Brain Health Registry SP STUDY CONFIRMATION
StudyPartnerID Unique identifier for study partners N/A N/A BHR_SP_RELATIONSHIP Brain Health Registry SP RELATIONSHIP
StudyPartnerID Unique identifier for study partners N/A N/A BHR_SP_INITIAL Brain Health Registry SP INITIAL
StudyPartnerID Unique identifier for study partners N/A N/A BHR_SP_FAQ Brain Health Registry SP FAQ
StudyPartnerID Unique identifier for study partners N/A N/A BHR_SP_EVERYDAY_COGNITION Brain Health Registry SP EVERYDAY COGNITION
StudyPartnerID Unique identifier for study partners N/A N/A BHR_SP_CAREGIVER_BURDEN Brain Health Registry SP CAREGIVER BURDEN
StudyPartnerID Unique identifier for study partners N/A N/A BHR_SP_ADL Brain Health Registry SP ADL
RID N/A N/A N/A BATEMANLAB_ADNI_Plasma_Abeta4240_20221118 Bateman Lab Plasma Abeta42:Abeta40 Ratio as a Predictor of Brain Amyloidosis [ADNI]
RID ADNI subject ID N/A N/A FNIH_PLASMA_PTAU181_PROJECT FNIH Biomarkers Consortium Plasma pTau-181 Project
RID Participant roster ID -4 N/A UCBERKELEYFBB_8MM UC Berkeley - FBB analysis
RID Participant roster ID -4 N/A UCBERKELEYFDG_8MM UC Berkeley - FDG analysis
RID N/A N/A N/A UCSDVOL Anders Dale Lab (UCSD) - Derived Volumes
RID Participant roster ID -4 N/A BHR_MEMTRAX Brain Health Registry MEMTRAX
QID34_2 How long has your current Paliperidone (Invega) prescription been stable (same frequency and dose)?... Months 1=0;2=0 ~ 0;3=0 ~ 1;4=0 ~ 2;5=0 ~ 3;6=0 ~ 4;7=0 ~ 5;8=0 ~ 6;9=0 ~ 7;10=0 ~ 8;11=0 ~ 9;12=0 ~ 10;13=0 ~ 11;14=1;15=1 ~ 0;16=1 ~ 1;17=1 ~ 2;18=1 ~ 3;19=1 ~ 4;20=1 ~ 5;21=1 ~ 6;22=1 ~ 7;23=1 ~ 8;24=1 ~ 9;25=1 ~ 10;26=1 ~ 11;27=2;28=2 ~ 0;29=2 ~ 1;30=2 ~ 2;31=2 ~ 3;32=2 ~ 4;33=2 ~ 5;34=2 ~ 6;35=2 ~ 7;36=2 ~ 8;37=2 ~ 9;38=2 ~ 10;39=2 ~ 11;40=3;41=3 ~ 0;42=3 ~ 1;43=3 ~ 2;44=3 ~ 3;45=3 ~ 4;46=3 ~ 5;47=3 ~ 6;48=3 ~ 7;49=3 ~ 8;50=3 ~ 9;51=3 ~ 10;52=3 ~ 11;53=4;54=4 ~ 0;55=4 ~ 1;56=4 ~ 2;57=4 ~ 3;58=4 ~ 4;59=4 ~ 5;60=4 ~ 6;61=4 ~ 7;62=4 ~ 8;63=4 ~ 9;64=4 ~ 10;65=4 ~ 11;66=5;67=5 ~ 0;68=5 ~ 1;69=5 ~ 2;70=5 ~ 3;71=5 ~ 4;72=5 ~ 5;73=5 ~ 6;74=5 ~ 7;75=5 ~ 8;76=5 ~ 9;77=5 ~ 10;78=5 ~ 11;79=6;80=6 ~ 0;81=6 ~ 1;82=6 ~ 2;83=6 ~ 3;84=6 ~ 4;85=6 ~ 5;86=6 ~ 6;87=6 ~ 7;88=6 ~ 8;89=6 ~ 9;90=6 ~ 10;91=6 ~ 11;92=7;93=7 ~ 0;94=7 ~ 1;95=7 ~ 2;96=7 ~ 3;97=7 ~ 4;98=7 ~ 5;99=7 ~ 6;100=7 ~ 7;101=7 ~ 8;102=7 ~ 9;103=7 ~ 10;104=7 ~ 11;105=8;106=8 ~ 0;107=8 ~ 1;108=8 ~ 2;109=8 ~ 3;110=8 ~ 4;111=8 ~ 5;112=8 ~ 6;113=8 ~ 7;114=8 ~ 8;115=8 ~ 9;116=8 ~ 10;117=8 ~ 11;118=9;119=9 ~ 0;120=9 ~ 1;121=9 ~ 2;122=9 ~ 3;123=9 ~ 4;124=9 ~ 5;125=9 ~ 6;126=9 ~ 7;127=9 ~ 8;128=9 ~ 9;129=9 ~ 10;130=9 ~ 11;131=10;132=10 ~ 0;133=10 ~ 1;134=10 ~ 2;135=10 ~ 3;136=10 ~ 4;137=10 ~ 5;138=10 ~ 6;139=10 ~ 7;140=10 ~ 8;141=10 ~ 9;142=10 ~ 10;143=10 ~ 11;144=11;145=11 ~ 0;146=11 ~ 1;147=11 ~ 2;148=11 ~ 3;149=11 ~ 4;150=11 ~ 5;151=11 ~ 6;152=11 ~ 7;153=11 ~ 8;154=11 ~ 9;155=11 ~ 10;156=11 ~ 11;157=12;158=12 ~ 0;159=12 ~ 1;160=12 ~ 2;161=12 ~ 3;162=12 ~ 4;163=12 ~ 5;164=12 ~ 6;165=12 ~ 7;166=12 ~ 8;167=12 ~ 9;168=12 ~ 10;169=12 ~ 11;170=13;171=13 ~ 0;172=13 ~ 1;173=13 ~ 2;174=13 ~ 3;175=13 ~ 4;176=13 ~ 5;177=13 ~ 6;178=13 ~ 7;179=13 ~ 8;180=13 ~ 9;181=13 ~ 10;182=13 ~ 11;183=14;184=14 ~ 0;185=14 ~ 1;186=14 ~ 2;187=14 ~ 3;188=14 ~ 4;189=14 ~ 5;190=14 ~ 6;191=14 ~ 7;192=14 ~ 8;193=14 ~ 9;194=14 ~ 10;195=14 ~ 11;196=15;197=15 ~ 0;198=15 ~ 1;199=15 ~ 2;200=15 ~ 3;201=15 ~ 4;202=15 ~ 5;203=15 ~ 6;204=15 ~ 7;205=15 ~ 8;206=15 ~ 9;207=15 ~ 10;208=15 ~ 11;209=16;210=16 ~ 0;211=16 ~ 1;212=16 ~ 2;213=16 ~ 3;214=16 ~ 4;215=16 ~ 5;216=16 ~ 6;217=16 ~ 7;218=16 ~ 8;219=16 ~ 9;220=16 ~ 10;221=16 ~ 11;222=17;223=17 ~ 0;224=17 ~ 1;225=17 ~ 2;226=17 ~ 3;227=17 ~ 4;228=17 ~ 5;229=17 ~ 6;230=17 ~ 7;231=17 ~ 8;232=17 ~ 9;233=17 ~ 10;234=17 ~ 11;235=18;236=18 ~ 0;237=18 ~ 1;238=18 ~ 2;239=18 ~ 3;240=18 ~ 4;241=18 ~ 5;242=18 ~ 6;243=18 ~ 7;244=18 ~ 8;245=18 ~ 9;246=18 ~ 10;247=18 ~ 11;248=19;249=19 ~ 0;250=19 ~ 1;251=19 ~ 2;252=19 ~ 3;253=19 ~ 4;254=19 ~ 5;255=19 ~ 6;256=19 ~ 7;257=19 ~ 8;258=19 ~ 9;259=19 ~ 10;260=19 ~ 11;261=20+;262=20+ ~ N/A BHR_BASELINE_QUESTIONNAIRE Brain Health Registry BASELINE QUESTIONNAIRE
QID34_1 How long has your current Paliperidone (Invega) prescription been stable (same frequency and dose)?... Years 1=0;2=0 ~ 0;3=0 ~ 1;4=0 ~ 2;5=0 ~ 3;6=0 ~ 4;7=0 ~ 5;8=0 ~ 6;9=0 ~ 7;10=0 ~ 8;11=0 ~ 9;12=0 ~ 10;13=0 ~ 11;14=1;15=1 ~ 0;16=1 ~ 1;17=1 ~ 2;18=1 ~ 3;19=1 ~ 4;20=1 ~ 5;21=1 ~ 6;22=1 ~ 7;23=1 ~ 8;24=1 ~ 9;25=1 ~ 10;26=1 ~ 11;27=2;28=2 ~ 0;29=2 ~ 1;30=2 ~ 2;31=2 ~ 3;32=2 ~ 4;33=2 ~ 5;34=2 ~ 6;35=2 ~ 7;36=2 ~ 8;37=2 ~ 9;38=2 ~ 10;39=2 ~ 11;40=3;41=3 ~ 0;42=3 ~ 1;43=3 ~ 2;44=3 ~ 3;45=3 ~ 4;46=3 ~ 5;47=3 ~ 6;48=3 ~ 7;49=3 ~ 8;50=3 ~ 9;51=3 ~ 10;52=3 ~ 11;53=4;54=4 ~ 0;55=4 ~ 1;56=4 ~ 2;57=4 ~ 3;58=4 ~ 4;59=4 ~ 5;60=4 ~ 6;61=4 ~ 7;62=4 ~ 8;63=4 ~ 9;64=4 ~ 10;65=4 ~ 11;66=5;67=5 ~ 0;68=5 ~ 1;69=5 ~ 2;70=5 ~ 3;71=5 ~ 4;72=5 ~ 5;73=5 ~ 6;74=5 ~ 7;75=5 ~ 8;76=5 ~ 9;77=5 ~ 10;78=5 ~ 11;79=6;80=6 ~ 0;81=6 ~ 1;82=6 ~ 2;83=6 ~ 3;84=6 ~ 4;85=6 ~ 5;86=6 ~ 6;87=6 ~ 7;88=6 ~ 8;89=6 ~ 9;90=6 ~ 10;91=6 ~ 11;92=7;93=7 ~ 0;94=7 ~ 1;95=7 ~ 2;96=7 ~ 3;97=7 ~ 4;98=7 ~ 5;99=7 ~ 6;100=7 ~ 7;101=7 ~ 8;102=7 ~ 9;103=7 ~ 10;104=7 ~ 11;105=8;106=8 ~ 0;107=8 ~ 1;108=8 ~ 2;109=8 ~ 3;110=8 ~ 4;111=8 ~ 5;112=8 ~ 6;113=8 ~ 7;114=8 ~ 8;115=8 ~ 9;116=8 ~ 10;117=8 ~ 11;118=9;119=9 ~ 0;120=9 ~ 1;121=9 ~ 2;122=9 ~ 3;123=9 ~ 4;124=9 ~ 5;125=9 ~ 6;126=9 ~ 7;127=9 ~ 8;128=9 ~ 9;129=9 ~ 10;130=9 ~ 11;131=10;132=10 ~ 0;133=10 ~ 1;134=10 ~ 2;135=10 ~ 3;136=10 ~ 4;137=10 ~ 5;138=10 ~ 6;139=10 ~ 7;140=10 ~ 8;141=10 ~ 9;142=10 ~ 10;143=10 ~ 11;144=11;145=11 ~ 0;146=11 ~ 1;147=11 ~ 2;148=11 ~ 3;149=11 ~ 4;150=11 ~ 5;151=11 ~ 6;152=11 ~ 7;153=11 ~ 8;154=11 ~ 9;155=11 ~ 10;156=11 ~ 11;157=12;158=12 ~ 0;159=12 ~ 1;160=12 ~ 2;161=12 ~ 3;162=12 ~ 4;163=12 ~ 5;164=12 ~ 6;165=12 ~ 7;166=12 ~ 8;167=12 ~ 9;168=12 ~ 10;169=12 ~ 11;170=13;171=13 ~ 0;172=13 ~ 1;173=13 ~ 2;174=13 ~ 3;175=13 ~ 4;176=13 ~ 5;177=13 ~ 6;178=13 ~ 7;179=13 ~ 8;180=13 ~ 9;181=13 ~ 10;182=13 ~ 11;183=14;184=14 ~ 0;185=14 ~ 1;186=14 ~ 2;187=14 ~ 3;188=14 ~ 4;189=14 ~ 5;190=14 ~ 6;191=14 ~ 7;192=14 ~ 8;193=14 ~ 9;194=14 ~ 10;195=14 ~ 11;196=15;197=15 ~ 0;198=15 ~ 1;199=15 ~ 2;200=15 ~ 3;201=15 ~ 4;202=15 ~ 5;203=15 ~ 6;204=15 ~ 7;205=15 ~ 8;206=15 ~ 9;207=15 ~ 10;208=15 ~ 11;209=16;210=16 ~ 0;211=16 ~ 1;212=16 ~ 2;213=16 ~ 3;214=16 ~ 4;215=16 ~ 5;216=16 ~ 6;217=16 ~ 7;218=16 ~ 8;219=16 ~ 9;220=16 ~ 10;221=16 ~ 11;222=17;223=17 ~ 0;224=17 ~ 1;225=17 ~ 2;226=17 ~ 3;227=17 ~ 4;228=17 ~ 5;229=17 ~ 6;230=17 ~ 7;231=17 ~ 8;232=17 ~ 9;233=17 ~ 10;234=17 ~ 11;235=18;236=18 ~ 0;237=18 ~ 1;238=18 ~ 2;239=18 ~ 3;240=18 ~ 4;241=18 ~ 5;242=18 ~ 6;243=18 ~ 7;244=18 ~ 8;245=18 ~ 9;246=18 ~ 10;247=18 ~ 11;248=19;249=19 ~ 0;250=19 ~ 1;251=19 ~ 2;252=19 ~ 3;253=19 ~ 4;254=19 ~ 5;255=19 ~ 6;256=19 ~ 7;257=19 ~ 8;258=19 ~ 9;259=19 ~ 10;260=19 ~ 11;261=20+;262=20+ ~ N/A BHR_BASELINE_QUESTIONNAIRE Brain Health Registry BASELINE QUESTIONNAIRE
QID33_2 How long has your current Risperidone (Risperdal) prescription been stable (same frequency and dose)?... Months 1=0;2=0 ~ 0;3=0 ~ 1;4=0 ~ 2;5=0 ~ 3;6=0 ~ 4;7=0 ~ 5;8=0 ~ 6;9=0 ~ 7;10=0 ~ 8;11=0 ~ 9;12=0 ~ 10;13=0 ~ 11;14=1;15=1 ~ 0;16=1 ~ 1;17=1 ~ 2;18=1 ~ 3;19=1 ~ 4;20=1 ~ 5;21=1 ~ 6;22=1 ~ 7;23=1 ~ 8;24=1 ~ 9;25=1 ~ 10;26=1 ~ 11;27=2;28=2 ~ 0;29=2 ~ 1;30=2 ~ 2;31=2 ~ 3;32=2 ~ 4;33=2 ~ 5;34=2 ~ 6;35=2 ~ 7;36=2 ~ 8;37=2 ~ 9;38=2 ~ 10;39=2 ~ 11;40=3;41=3 ~ 0;42=3 ~ 1;43=3 ~ 2;44=3 ~ 3;45=3 ~ 4;46=3 ~ 5;47=3 ~ 6;48=3 ~ 7;49=3 ~ 8;50=3 ~ 9;51=3 ~ 10;52=3 ~ 11;53=4;54=4 ~ 0;55=4 ~ 1;56=4 ~ 2;57=4 ~ 3;58=4 ~ 4;59=4 ~ 5;60=4 ~ 6;61=4 ~ 7;62=4 ~ 8;63=4 ~ 9;64=4 ~ 10;65=4 ~ 11;66=5;67=5 ~ 0;68=5 ~ 1;69=5 ~ 2;70=5 ~ 3;71=5 ~ 4;72=5 ~ 5;73=5 ~ 6;74=5 ~ 7;75=5 ~ 8;76=5 ~ 9;77=5 ~ 10;78=5 ~ 11;79=6;80=6 ~ 0;81=6 ~ 1;82=6 ~ 2;83=6 ~ 3;84=6 ~ 4;85=6 ~ 5;86=6 ~ 6;87=6 ~ 7;88=6 ~ 8;89=6 ~ 9;90=6 ~ 10;91=6 ~ 11;92=7;93=7 ~ 0;94=7 ~ 1;95=7 ~ 2;96=7 ~ 3;97=7 ~ 4;98=7 ~ 5;99=7 ~ 6;100=7 ~ 7;101=7 ~ 8;102=7 ~ 9;103=7 ~ 10;104=7 ~ 11;105=8;106=8 ~ 0;107=8 ~ 1;108=8 ~ 2;109=8 ~ 3;110=8 ~ 4;111=8 ~ 5;112=8 ~ 6;113=8 ~ 7;114=8 ~ 8;115=8 ~ 9;116=8 ~ 10;117=8 ~ 11;118=9;119=9 ~ 0;120=9 ~ 1;121=9 ~ 2;122=9 ~ 3;123=9 ~ 4;124=9 ~ 5;125=9 ~ 6;126=9 ~ 7;127=9 ~ 8;128=9 ~ 9;129=9 ~ 10;130=9 ~ 11;131=10;132=10 ~ 0;133=10 ~ 1;134=10 ~ 2;135=10 ~ 3;136=10 ~ 4;137=10 ~ 5;138=10 ~ 6;139=10 ~ 7;140=10 ~ 8;141=10 ~ 9;142=10 ~ 10;143=10 ~ 11;144=11;145=11 ~ 0;146=11 ~ 1;147=11 ~ 2;148=11 ~ 3;149=11 ~ 4;150=11 ~ 5;151=11 ~ 6;152=11 ~ 7;153=11 ~ 8;154=11 ~ 9;155=11 ~ 10;156=11 ~ 11;157=12;158=12 ~ 0;159=12 ~ 1;160=12 ~ 2;161=12 ~ 3;162=12 ~ 4;163=12 ~ 5;164=12 ~ 6;165=12 ~ 7;166=12 ~ 8;167=12 ~ 9;168=12 ~ 10;169=12 ~ 11;170=13;171=13 ~ 0;172=13 ~ 1;173=13 ~ 2;174=13 ~ 3;175=13 ~ 4;176=13 ~ 5;177=13 ~ 6;178=13 ~ 7;179=13 ~ 8;180=13 ~ 9;181=13 ~ 10;182=13 ~ 11;183=14;184=14 ~ 0;185=14 ~ 1;186=14 ~ 2;187=14 ~ 3;188=14 ~ 4;189=14 ~ 5;190=14 ~ 6;191=14 ~ 7;192=14 ~ 8;193=14 ~ 9;194=14 ~ 10;195=14 ~ 11;196=15;197=15 ~ 0;198=15 ~ 1;199=15 ~ 2;200=15 ~ 3;201=15 ~ 4;202=15 ~ 5;203=15 ~ 6;204=15 ~ 7;205=15 ~ 8;206=15 ~ 9;207=15 ~ 10;208=15 ~ 11;209=16;210=16 ~ 0;211=16 ~ 1;212=16 ~ 2;213=16 ~ 3;214=16 ~ 4;215=16 ~ 5;216=16 ~ 6;217=16 ~ 7;218=16 ~ 8;219=16 ~ 9;220=16 ~ 10;221=16 ~ 11;222=17;223=17 ~ 0;224=17 ~ 1;225=17 ~ 2;226=17 ~ 3;227=17 ~ 4;228=17 ~ 5;229=17 ~ 6;230=17 ~ 7;231=17 ~ 8;232=17 ~ 9;233=17 ~ 10;234=17 ~ 11;235=18;236=18 ~ 0;237=18 ~ 1;238=18 ~ 2;239=18 ~ 3;240=18 ~ 4;241=18 ~ 5;242=18 ~ 6;243=18 ~ 7;244=18 ~ 8;245=18 ~ 9;246=18 ~ 10;247=18 ~ 11;248=19;249=19 ~ 0;250=19 ~ 1;251=19 ~ 2;252=19 ~ 3;253=19 ~ 4;254=19 ~ 5;255=19 ~ 6;256=19 ~ 7;257=19 ~ 8;258=19 ~ 9;259=19 ~ 10;260=19 ~ 11;261=20+;262=20+ ~ N/A BHR_BASELINE_QUESTIONNAIRE Brain Health Registry BASELINE QUESTIONNAIRE
QID33_1 How long has your current Risperidone (Risperdal) prescription been stable (same frequency and dose)?... Years 1=0;2=0 ~ 0;3=0 ~ 1;4=0 ~ 2;5=0 ~ 3;6=0 ~ 4;7=0 ~ 5;8=0 ~ 6;9=0 ~ 7;10=0 ~ 8;11=0 ~ 9;12=0 ~ 10;13=0 ~ 11;14=1;15=1 ~ 0;16=1 ~ 1;17=1 ~ 2;18=1 ~ 3;19=1 ~ 4;20=1 ~ 5;21=1 ~ 6;22=1 ~ 7;23=1 ~ 8;24=1 ~ 9;25=1 ~ 10;26=1 ~ 11;27=2;28=2 ~ 0;29=2 ~ 1;30=2 ~ 2;31=2 ~ 3;32=2 ~ 4;33=2 ~ 5;34=2 ~ 6;35=2 ~ 7;36=2 ~ 8;37=2 ~ 9;38=2 ~ 10;39=2 ~ 11;40=3;41=3 ~ 0;42=3 ~ 1;43=3 ~ 2;44=3 ~ 3;45=3 ~ 4;46=3 ~ 5;47=3 ~ 6;48=3 ~ 7;49=3 ~ 8;50=3 ~ 9;51=3 ~ 10;52=3 ~ 11;53=4;54=4 ~ 0;55=4 ~ 1;56=4 ~ 2;57=4 ~ 3;58=4 ~ 4;59=4 ~ 5;60=4 ~ 6;61=4 ~ 7;62=4 ~ 8;63=4 ~ 9;64=4 ~ 10;65=4 ~ 11;66=5;67=5 ~ 0;68=5 ~ 1;69=5 ~ 2;70=5 ~ 3;71=5 ~ 4;72=5 ~ 5;73=5 ~ 6;74=5 ~ 7;75=5 ~ 8;76=5 ~ 9;77=5 ~ 10;78=5 ~ 11;79=6;80=6 ~ 0;81=6 ~ 1;82=6 ~ 2;83=6 ~ 3;84=6 ~ 4;85=6 ~ 5;86=6 ~ 6;87=6 ~ 7;88=6 ~ 8;89=6 ~ 9;90=6 ~ 10;91=6 ~ 11;92=7;93=7 ~ 0;94=7 ~ 1;95=7 ~ 2;96=7 ~ 3;97=7 ~ 4;98=7 ~ 5;99=7 ~ 6;100=7 ~ 7;101=7 ~ 8;102=7 ~ 9;103=7 ~ 10;104=7 ~ 11;105=8;106=8 ~ 0;107=8 ~ 1;108=8 ~ 2;109=8 ~ 3;110=8 ~ 4;111=8 ~ 5;112=8 ~ 6;113=8 ~ 7;114=8 ~ 8;115=8 ~ 9;116=8 ~ 10;117=8 ~ 11;118=9;119=9 ~ 0;120=9 ~ 1;121=9 ~ 2;122=9 ~ 3;123=9 ~ 4;124=9 ~ 5;125=9 ~ 6;126=9 ~ 7;127=9 ~ 8;128=9 ~ 9;129=9 ~ 10;130=9 ~ 11;131=10;132=10 ~ 0;133=10 ~ 1;134=10 ~ 2;135=10 ~ 3;136=10 ~ 4;137=10 ~ 5;138=10 ~ 6;139=10 ~ 7;140=10 ~ 8;141=10 ~ 9;142=10 ~ 10;143=10 ~ 11;144=11;145=11 ~ 0;146=11 ~ 1;147=11 ~ 2;148=11 ~ 3;149=11 ~ 4;150=11 ~ 5;151=11 ~ 6;152=11 ~ 7;153=11 ~ 8;154=11 ~ 9;155=11 ~ 10;156=11 ~ 11;157=12;158=12 ~ 0;159=12 ~ 1;160=12 ~ 2;161=12 ~ 3;162=12 ~ 4;163=12 ~ 5;164=12 ~ 6;165=12 ~ 7;166=12 ~ 8;167=12 ~ 9;168=12 ~ 10;169=12 ~ 11;170=13;171=13 ~ 0;172=13 ~ 1;173=13 ~ 2;174=13 ~ 3;175=13 ~ 4;176=13 ~ 5;177=13 ~ 6;178=13 ~ 7;179=13 ~ 8;180=13 ~ 9;181=13 ~ 10;182=13 ~ 11;183=14;184=14 ~ 0;185=14 ~ 1;186=14 ~ 2;187=14 ~ 3;188=14 ~ 4;189=14 ~ 5;190=14 ~ 6;191=14 ~ 7;192=14 ~ 8;193=14 ~ 9;194=14 ~ 10;195=14 ~ 11;196=15;197=15 ~ 0;198=15 ~ 1;199=15 ~ 2;200=15 ~ 3;201=15 ~ 4;202=15 ~ 5;203=15 ~ 6;204=15 ~ 7;205=15 ~ 8;206=15 ~ 9;207=15 ~ 10;208=15 ~ 11;209=16;210=16 ~ 0;211=16 ~ 1;212=16 ~ 2;213=16 ~ 3;214=16 ~ 4;215=16 ~ 5;216=16 ~ 6;217=16 ~ 7;218=16 ~ 8;219=16 ~ 9;220=16 ~ 10;221=16 ~ 11;222=17;223=17 ~ 0;224=17 ~ 1;225=17 ~ 2;226=17 ~ 3;227=17 ~ 4;228=17 ~ 5;229=17 ~ 6;230=17 ~ 7;231=17 ~ 8;232=17 ~ 9;233=17 ~ 10;234=17 ~ 11;235=18;236=18 ~ 0;237=18 ~ 1;238=18 ~ 2;239=18 ~ 3;240=18 ~ 4;241=18 ~ 5;242=18 ~ 6;243=18 ~ 7;244=18 ~ 8;245=18 ~ 9;246=18 ~ 10;247=18 ~ 11;248=19;249=19 ~ 0;250=19 ~ 1;251=19 ~ 2;252=19 ~ 3;253=19 ~ 4;254=19 ~ 5;255=19 ~ 6;256=19 ~ 7;257=19 ~ 8;258=19 ~ 9;259=19 ~ 10;260=19 ~ 11;261=20+;262=20+ ~ N/A BHR_BASELINE_QUESTIONNAIRE Brain Health Registry BASELINE QUESTIONNAIRE
QID2_4 Please answer the following questions using the responses provided.... Playing a game of skill such as bridge or chess, or working on a hobby. 1=Normal;2=Never did, but could do now;3=Never did, would have difficulty now;4=Has difficulty, but does by self;5=Requires assistance;6=Dependent N/A BHR_SP_ADL Brain Health Registry SP ADL
QID40_2 How long has your current Paliperidone (Invega) prescription been stable (same frequency and dose)?... Months 1=0;2=0 ~ 0;3=0 ~ 1;4=0 ~ 2;5=0 ~ 3;6=0 ~ 4;7=0 ~ 5;8=0 ~ 6;9=0 ~ 7;10=0 ~ 8;11=0 ~ 9;12=0 ~ 10;13=0 ~ 11;14=1;15=1 ~ 0;16=1 ~ 1;17=1 ~ 2;18=1 ~ 3;19=1 ~ 4;20=1 ~ 5;21=1 ~ 6;22=1 ~ 7;23=1 ~ 8;24=1 ~ 9;25=1 ~ 10;26=1 ~ 11;27=2;28=2 ~ 0;29=2 ~ 1;30=2 ~ 2;31=2 ~ 3;32=2 ~ 4;33=2 ~ 5;34=2 ~ 6;35=2 ~ 7;36=2 ~ 8;37=2 ~ 9;38=2 ~ 10;39=2 ~ 11;40=3;41=3 ~ 0;42=3 ~ 1;43=3 ~ 2;44=3 ~ 3;45=3 ~ 4;46=3 ~ 5;47=3 ~ 6;48=3 ~ 7;49=3 ~ 8;50=3 ~ 9;51=3 ~ 10;52=3 ~ 11;53=4;54=4 ~ 0;55=4 ~ 1;56=4 ~ 2;57=4 ~ 3;58=4 ~ 4;59=4 ~ 5;60=4 ~ 6;61=4 ~ 7;62=4 ~ 8;63=4 ~ 9;64=4 ~ 10;65=4 ~ 11;66=5;67=5 ~ 0;68=5 ~ 1;69=5 ~ 2;70=5 ~ 3;71=5 ~ 4;72=5 ~ 5;73=5 ~ 6;74=5 ~ 7;75=5 ~ 8;76=5 ~ 9;77=5 ~ 10;78=5 ~ 11;79=6;80=6 ~ 0;81=6 ~ 1;82=6 ~ 2;83=6 ~ 3;84=6 ~ 4;85=6 ~ 5;86=6 ~ 6;87=6 ~ 7;88=6 ~ 8;89=6 ~ 9;90=6 ~ 10;91=6 ~ 11;92=7;93=7 ~ 0;94=7 ~ 1;95=7 ~ 2;96=7 ~ 3;97=7 ~ 4;98=7 ~ 5;99=7 ~ 6;100=7 ~ 7;101=7 ~ 8;102=7 ~ 9;103=7 ~ 10;104=7 ~ 11;105=8;106=8 ~ 0;107=8 ~ 1;108=8 ~ 2;109=8 ~ 3;110=8 ~ 4;111=8 ~ 5;112=8 ~ 6;113=8 ~ 7;114=8 ~ 8;115=8 ~ 9;116=8 ~ 10;117=8 ~ 11;118=9;119=9 ~ 0;120=9 ~ 1;121=9 ~ 2;122=9 ~ 3;123=9 ~ 4;124=9 ~ 5;125=9 ~ 6;126=9 ~ 7;127=9 ~ 8;128=9 ~ 9;129=9 ~ 10;130=9 ~ 11;131=10;132=10 ~ 0;133=10 ~ 1;134=10 ~ 2;135=10 ~ 3;136=10 ~ 4;137=10 ~ 5;138=10 ~ 6;139=10 ~ 7;140=10 ~ 8;141=10 ~ 9;142=10 ~ 10;143=10 ~ 11;144=11;145=11 ~ 0;146=11 ~ 1;147=11 ~ 2;148=11 ~ 3;149=11 ~ 4;150=11 ~ 5;151=11 ~ 6;152=11 ~ 7;153=11 ~ 8;154=11 ~ 9;155=11 ~ 10;156=11 ~ 11;157=12;158=12 ~ 0;159=12 ~ 1;160=12 ~ 2;161=12 ~ 3;162=12 ~ 4;163=12 ~ 5;164=12 ~ 6;165=12 ~ 7;166=12 ~ 8;167=12 ~ 9;168=12 ~ 10;169=12 ~ 11;170=13;171=13 ~ 0;172=13 ~ 1;173=13 ~ 2;174=13 ~ 3;175=13 ~ 4;176=13 ~ 5;177=13 ~ 6;178=13 ~ 7;179=13 ~ 8;180=13 ~ 9;181=13 ~ 10;182=13 ~ 11;183=14;184=14 ~ 0;185=14 ~ 1;186=14 ~ 2;187=14 ~ 3;188=14 ~ 4;189=14 ~ 5;190=14 ~ 6;191=14 ~ 7;192=14 ~ 8;193=14 ~ 9;194=14 ~ 10;195=14 ~ 11;196=15;197=15 ~ 0;198=15 ~ 1;199=15 ~ 2;200=15 ~ 3;201=15 ~ 4;202=15 ~ 5;203=15 ~ 6;204=15 ~ 7;205=15 ~ 8;206=15 ~ 9;207=15 ~ 10;208=15 ~ 11;209=16;210=16 ~ 0;211=16 ~ 1;212=16 ~ 2;213=16 ~ 3;214=16 ~ 4;215=16 ~ 5;216=16 ~ 6;217=16 ~ 7;218=16 ~ 8;219=16 ~ 9;220=16 ~ 10;221=16 ~ 11;222=17;223=17 ~ 0;224=17 ~ 1;225=17 ~ 2;226=17 ~ 3;227=17 ~ 4;228=17 ~ 5;229=17 ~ 6;230=17 ~ 7;231=17 ~ 8;232=17 ~ 9;233=17 ~ 10;234=17 ~ 11;235=18;236=18 ~ 0;237=18 ~ 1;238=18 ~ 2;239=18 ~ 3;240=18 ~ 4;241=18 ~ 5;242=18 ~ 6;243=18 ~ 7;244=18 ~ 8;245=18 ~ 9;246=18 ~ 10;247=18 ~ 11;248=19;249=19 ~ 0;250=19 ~ 1;251=19 ~ 2;252=19 ~ 3;253=19 ~ 4;254=19 ~ 5;255=19 ~ 6;256=19 ~ 7;257=19 ~ 8;258=19 ~ 9;259=19 ~ 10;260=19 ~ 11;261=20+;262=20+ ~ N/A BHR_LONGITUDINAL_QUESTIONNAIRE Brain Health Registry LONGITUDINAL QUESTIONNAIRE
QID40_1 How long has your current Paliperidone (Invega) prescription been stable (same frequency and dose)?... Years 1=0;2=0 ~ 0;3=0 ~ 1;4=0 ~ 2;5=0 ~ 3;6=0 ~ 4;7=0 ~ 5;8=0 ~ 6;9=0 ~ 7;10=0 ~ 8;11=0 ~ 9;12=0 ~ 10;13=0 ~ 11;14=1;15=1 ~ 0;16=1 ~ 1;17=1 ~ 2;18=1 ~ 3;19=1 ~ 4;20=1 ~ 5;21=1 ~ 6;22=1 ~ 7;23=1 ~ 8;24=1 ~ 9;25=1 ~ 10;26=1 ~ 11;27=2;28=2 ~ 0;29=2 ~ 1;30=2 ~ 2;31=2 ~ 3;32=2 ~ 4;33=2 ~ 5;34=2 ~ 6;35=2 ~ 7;36=2 ~ 8;37=2 ~ 9;38=2 ~ 10;39=2 ~ 11;40=3;41=3 ~ 0;42=3 ~ 1;43=3 ~ 2;44=3 ~ 3;45=3 ~ 4;46=3 ~ 5;47=3 ~ 6;48=3 ~ 7;49=3 ~ 8;50=3 ~ 9;51=3 ~ 10;52=3 ~ 11;53=4;54=4 ~ 0;55=4 ~ 1;56=4 ~ 2;57=4 ~ 3;58=4 ~ 4;59=4 ~ 5;60=4 ~ 6;61=4 ~ 7;62=4 ~ 8;63=4 ~ 9;64=4 ~ 10;65=4 ~ 11;66=5;67=5 ~ 0;68=5 ~ 1;69=5 ~ 2;70=5 ~ 3;71=5 ~ 4;72=5 ~ 5;73=5 ~ 6;74=5 ~ 7;75=5 ~ 8;76=5 ~ 9;77=5 ~ 10;78=5 ~ 11;79=6;80=6 ~ 0;81=6 ~ 1;82=6 ~ 2;83=6 ~ 3;84=6 ~ 4;85=6 ~ 5;86=6 ~ 6;87=6 ~ 7;88=6 ~ 8;89=6 ~ 9;90=6 ~ 10;91=6 ~ 11;92=7;93=7 ~ 0;94=7 ~ 1;95=7 ~ 2;96=7 ~ 3;97=7 ~ 4;98=7 ~ 5;99=7 ~ 6;100=7 ~ 7;101=7 ~ 8;102=7 ~ 9;103=7 ~ 10;104=7 ~ 11;105=8;106=8 ~ 0;107=8 ~ 1;108=8 ~ 2;109=8 ~ 3;110=8 ~ 4;111=8 ~ 5;112=8 ~ 6;113=8 ~ 7;114=8 ~ 8;115=8 ~ 9;116=8 ~ 10;117=8 ~ 11;118=9;119=9 ~ 0;120=9 ~ 1;121=9 ~ 2;122=9 ~ 3;123=9 ~ 4;124=9 ~ 5;125=9 ~ 6;126=9 ~ 7;127=9 ~ 8;128=9 ~ 9;129=9 ~ 10;130=9 ~ 11;131=10;132=10 ~ 0;133=10 ~ 1;134=10 ~ 2;135=10 ~ 3;136=10 ~ 4;137=10 ~ 5;138=10 ~ 6;139=10 ~ 7;140=10 ~ 8;141=10 ~ 9;142=10 ~ 10;143=10 ~ 11;144=11;145=11 ~ 0;146=11 ~ 1;147=11 ~ 2;148=11 ~ 3;149=11 ~ 4;150=11 ~ 5;151=11 ~ 6;152=11 ~ 7;153=11 ~ 8;154=11 ~ 9;155=11 ~ 10;156=11 ~ 11;157=12;158=12 ~ 0;159=12 ~ 1;160=12 ~ 2;161=12 ~ 3;162=12 ~ 4;163=12 ~ 5;164=12 ~ 6;165=12 ~ 7;166=12 ~ 8;167=12 ~ 9;168=12 ~ 10;169=12 ~ 11;170=13;171=13 ~ 0;172=13 ~ 1;173=13 ~ 2;174=13 ~ 3;175=13 ~ 4;176=13 ~ 5;177=13 ~ 6;178=13 ~ 7;179=13 ~ 8;180=13 ~ 9;181=13 ~ 10;182=13 ~ 11;183=14;184=14 ~ 0;185=14 ~ 1;186=14 ~ 2;187=14 ~ 3;188=14 ~ 4;189=14 ~ 5;190=14 ~ 6;191=14 ~ 7;192=14 ~ 8;193=14 ~ 9;194=14 ~ 10;195=14 ~ 11;196=15;197=15 ~ 0;198=15 ~ 1;199=15 ~ 2;200=15 ~ 3;201=15 ~ 4;202=15 ~ 5;203=15 ~ 6;204=15 ~ 7;205=15 ~ 8;206=15 ~ 9;207=15 ~ 10;208=15 ~ 11;209=16;210=16 ~ 0;211=16 ~ 1;212=16 ~ 2;213=16 ~ 3;214=16 ~ 4;215=16 ~ 5;216=16 ~ 6;217=16 ~ 7;218=16 ~ 8;219=16 ~ 9;220=16 ~ 10;221=16 ~ 11;222=17;223=17 ~ 0;224=17 ~ 1;225=17 ~ 2;226=17 ~ 3;227=17 ~ 4;228=17 ~ 5;229=17 ~ 6;230=17 ~ 7;231=17 ~ 8;232=17 ~ 9;233=17 ~ 10;234=17 ~ 11;235=18;236=18 ~ 0;237=18 ~ 1;238=18 ~ 2;239=18 ~ 3;240=18 ~ 4;241=18 ~ 5;242=18 ~ 6;243=18 ~ 7;244=18 ~ 8;245=18 ~ 9;246=18 ~ 10;247=18 ~ 11;248=19;249=19 ~ 0;250=19 ~ 1;251=19 ~ 2;252=19 ~ 3;253=19 ~ 4;254=19 ~ 5;255=19 ~ 6;256=19 ~ 7;257=19 ~ 8;258=19 ~ 9;259=19 ~ 10;260=19 ~ 11;261=20+;262=20+ ~ N/A BHR_LONGITUDINAL_QUESTIONNAIRE Brain Health Registry LONGITUDINAL QUESTIONNAIRE
QID3_4 Select the most accurate representation of YOUR STUDY PARTNER'S level of ability to perform each activity over the preceding four weeks.... Playing a game of skill such as bridge or chess, working on a hobby. 1=Normal;2=Never did, but could now do;3=Never did, would have difficulty now;4=Has difficulty, but does by self;5=Requires assistance;6=Dependent N/A BHR_SP_FAQ Brain Health Registry SP FAQ
QID39_2 How long has your current Risperidone (Risperdal) prescription been stable (same frequency and dose)?... Months 1=0;2=0 ~ 0;3=0 ~ 1;4=0 ~ 2;5=0 ~ 3;6=0 ~ 4;7=0 ~ 5;8=0 ~ 6;9=0 ~ 7;10=0 ~ 8;11=0 ~ 9;12=0 ~ 10;13=0 ~ 11;14=1;15=1 ~ 0;16=1 ~ 1;17=1 ~ 2;18=1 ~ 3;19=1 ~ 4;20=1 ~ 5;21=1 ~ 6;22=1 ~ 7;23=1 ~ 8;24=1 ~ 9;25=1 ~ 10;26=1 ~ 11;27=2;28=2 ~ 0;29=2 ~ 1;30=2 ~ 2;31=2 ~ 3;32=2 ~ 4;33=2 ~ 5;34=2 ~ 6;35=2 ~ 7;36=2 ~ 8;37=2 ~ 9;38=2 ~ 10;39=2 ~ 11;40=3;41=3 ~ 0;42=3 ~ 1;43=3 ~ 2;44=3 ~ 3;45=3 ~ 4;46=3 ~ 5;47=3 ~ 6;48=3 ~ 7;49=3 ~ 8;50=3 ~ 9;51=3 ~ 10;52=3 ~ 11;53=4;54=4 ~ 0;55=4 ~ 1;56=4 ~ 2;57=4 ~ 3;58=4 ~ 4;59=4 ~ 5;60=4 ~ 6;61=4 ~ 7;62=4 ~ 8;63=4 ~ 9;64=4 ~ 10;65=4 ~ 11;66=5;67=5 ~ 0;68=5 ~ 1;69=5 ~ 2;70=5 ~ 3;71=5 ~ 4;72=5 ~ 5;73=5 ~ 6;74=5 ~ 7;75=5 ~ 8;76=5 ~ 9;77=5 ~ 10;78=5 ~ 11;79=6;80=6 ~ 0;81=6 ~ 1;82=6 ~ 2;83=6 ~ 3;84=6 ~ 4;85=6 ~ 5;86=6 ~ 6;87=6 ~ 7;88=6 ~ 8;89=6 ~ 9;90=6 ~ 10;91=6 ~ 11;92=7;93=7 ~ 0;94=7 ~ 1;95=7 ~ 2;96=7 ~ 3;97=7 ~ 4;98=7 ~ 5;99=7 ~ 6;100=7 ~ 7;101=7 ~ 8;102=7 ~ 9;103=7 ~ 10;104=7 ~ 11;105=8;106=8 ~ 0;107=8 ~ 1;108=8 ~ 2;109=8 ~ 3;110=8 ~ 4;111=8 ~ 5;112=8 ~ 6;113=8 ~ 7;114=8 ~ 8;115=8 ~ 9;116=8 ~ 10;117=8 ~ 11;118=9;119=9 ~ 0;120=9 ~ 1;121=9 ~ 2;122=9 ~ 3;123=9 ~ 4;124=9 ~ 5;125=9 ~ 6;126=9 ~ 7;127=9 ~ 8;128=9 ~ 9;129=9 ~ 10;130=9 ~ 11;131=10;132=10 ~ 0;133=10 ~ 1;134=10 ~ 2;135=10 ~ 3;136=10 ~ 4;137=10 ~ 5;138=10 ~ 6;139=10 ~ 7;140=10 ~ 8;141=10 ~ 9;142=10 ~ 10;143=10 ~ 11;144=11;145=11 ~ 0;146=11 ~ 1;147=11 ~ 2;148=11 ~ 3;149=11 ~ 4;150=11 ~ 5;151=11 ~ 6;152=11 ~ 7;153=11 ~ 8;154=11 ~ 9;155=11 ~ 10;156=11 ~ 11;157=12;158=12 ~ 0;159=12 ~ 1;160=12 ~ 2;161=12 ~ 3;162=12 ~ 4;163=12 ~ 5;164=12 ~ 6;165=12 ~ 7;166=12 ~ 8;167=12 ~ 9;168=12 ~ 10;169=12 ~ 11;170=13;171=13 ~ 0;172=13 ~ 1;173=13 ~ 2;174=13 ~ 3;175=13 ~ 4;176=13 ~ 5;177=13 ~ 6;178=13 ~ 7;179=13 ~ 8;180=13 ~ 9;181=13 ~ 10;182=13 ~ 11;183=14;184=14 ~ 0;185=14 ~ 1;186=14 ~ 2;187=14 ~ 3;188=14 ~ 4;189=14 ~ 5;190=14 ~ 6;191=14 ~ 7;192=14 ~ 8;193=14 ~ 9;194=14 ~ 10;195=14 ~ 11;196=15;197=15 ~ 0;198=15 ~ 1;199=15 ~ 2;200=15 ~ 3;201=15 ~ 4;202=15 ~ 5;203=15 ~ 6;204=15 ~ 7;205=15 ~ 8;206=15 ~ 9;207=15 ~ 10;208=15 ~ 11;209=16;210=16 ~ 0;211=16 ~ 1;212=16 ~ 2;213=16 ~ 3;214=16 ~ 4;215=16 ~ 5;216=16 ~ 6;217=16 ~ 7;218=16 ~ 8;219=16 ~ 9;220=16 ~ 10;221=16 ~ 11;222=17;223=17 ~ 0;224=17 ~ 1;225=17 ~ 2;226=17 ~ 3;227=17 ~ 4;228=17 ~ 5;229=17 ~ 6;230=17 ~ 7;231=17 ~ 8;232=17 ~ 9;233=17 ~ 10;234=17 ~ 11;235=18;236=18 ~ 0;237=18 ~ 1;238=18 ~ 2;239=18 ~ 3;240=18 ~ 4;241=18 ~ 5;242=18 ~ 6;243=18 ~ 7;244=18 ~ 8;245=18 ~ 9;246=18 ~ 10;247=18 ~ 11;248=19;249=19 ~ 0;250=19 ~ 1;251=19 ~ 2;252=19 ~ 3;253=19 ~ 4;254=19 ~ 5;255=19 ~ 6;256=19 ~ 7;257=19 ~ 8;258=19 ~ 9;259=19 ~ 10;260=19 ~ 11;261=20+;262=20+ ~ N/A BHR_LONGITUDINAL_QUESTIONNAIRE Brain Health Registry LONGITUDINAL QUESTIONNAIRE
QID39_1 How long has your current Risperidone (Risperdal) prescription been stable (same frequency and dose)?... Years 1=0;2=0 ~ 0;3=0 ~ 1;4=0 ~ 2;5=0 ~ 3;6=0 ~ 4;7=0 ~ 5;8=0 ~ 6;9=0 ~ 7;10=0 ~ 8;11=0 ~ 9;12=0 ~ 10;13=0 ~ 11;14=1;15=1 ~ 0;16=1 ~ 1;17=1 ~ 2;18=1 ~ 3;19=1 ~ 4;20=1 ~ 5;21=1 ~ 6;22=1 ~ 7;23=1 ~ 8;24=1 ~ 9;25=1 ~ 10;26=1 ~ 11;27=2;28=2 ~ 0;29=2 ~ 1;30=2 ~ 2;31=2 ~ 3;32=2 ~ 4;33=2 ~ 5;34=2 ~ 6;35=2 ~ 7;36=2 ~ 8;37=2 ~ 9;38=2 ~ 10;39=2 ~ 11;40=3;41=3 ~ 0;42=3 ~ 1;43=3 ~ 2;44=3 ~ 3;45=3 ~ 4;46=3 ~ 5;47=3 ~ 6;48=3 ~ 7;49=3 ~ 8;50=3 ~ 9;51=3 ~ 10;52=3 ~ 11;53=4;54=4 ~ 0;55=4 ~ 1;56=4 ~ 2;57=4 ~ 3;58=4 ~ 4;59=4 ~ 5;60=4 ~ 6;61=4 ~ 7;62=4 ~ 8;63=4 ~ 9;64=4 ~ 10;65=4 ~ 11;66=5;67=5 ~ 0;68=5 ~ 1;69=5 ~ 2;70=5 ~ 3;71=5 ~ 4;72=5 ~ 5;73=5 ~ 6;74=5 ~ 7;75=5 ~ 8;76=5 ~ 9;77=5 ~ 10;78=5 ~ 11;79=6;80=6 ~ 0;81=6 ~ 1;82=6 ~ 2;83=6 ~ 3;84=6 ~ 4;85=6 ~ 5;86=6 ~ 6;87=6 ~ 7;88=6 ~ 8;89=6 ~ 9;90=6 ~ 10;91=6 ~ 11;92=7;93=7 ~ 0;94=7 ~ 1;95=7 ~ 2;96=7 ~ 3;97=7 ~ 4;98=7 ~ 5;99=7 ~ 6;100=7 ~ 7;101=7 ~ 8;102=7 ~ 9;103=7 ~ 10;104=7 ~ 11;105=8;106=8 ~ 0;107=8 ~ 1;108=8 ~ 2;109=8 ~ 3;110=8 ~ 4;111=8 ~ 5;112=8 ~ 6;113=8 ~ 7;114=8 ~ 8;115=8 ~ 9;116=8 ~ 10;117=8 ~ 11;118=9;119=9 ~ 0;120=9 ~ 1;121=9 ~ 2;122=9 ~ 3;123=9 ~ 4;124=9 ~ 5;125=9 ~ 6;126=9 ~ 7;127=9 ~ 8;128=9 ~ 9;129=9 ~ 10;130=9 ~ 11;131=10;132=10 ~ 0;133=10 ~ 1;134=10 ~ 2;135=10 ~ 3;136=10 ~ 4;137=10 ~ 5;138=10 ~ 6;139=10 ~ 7;140=10 ~ 8;141=10 ~ 9;142=10 ~ 10;143=10 ~ 11;144=11;145=11 ~ 0;146=11 ~ 1;147=11 ~ 2;148=11 ~ 3;149=11 ~ 4;150=11 ~ 5;151=11 ~ 6;152=11 ~ 7;153=11 ~ 8;154=11 ~ 9;155=11 ~ 10;156=11 ~ 11;157=12;158=12 ~ 0;159=12 ~ 1;160=12 ~ 2;161=12 ~ 3;162=12 ~ 4;163=12 ~ 5;164=12 ~ 6;165=12 ~ 7;166=12 ~ 8;167=12 ~ 9;168=12 ~ 10;169=12 ~ 11;170=13;171=13 ~ 0;172=13 ~ 1;173=13 ~ 2;174=13 ~ 3;175=13 ~ 4;176=13 ~ 5;177=13 ~ 6;178=13 ~ 7;179=13 ~ 8;180=13 ~ 9;181=13 ~ 10;182=13 ~ 11;183=14;184=14 ~ 0;185=14 ~ 1;186=14 ~ 2;187=14 ~ 3;188=14 ~ 4;189=14 ~ 5;190=14 ~ 6;191=14 ~ 7;192=14 ~ 8;193=14 ~ 9;194=14 ~ 10;195=14 ~ 11;196=15;197=15 ~ 0;198=15 ~ 1;199=15 ~ 2;200=15 ~ 3;201=15 ~ 4;202=15 ~ 5;203=15 ~ 6;204=15 ~ 7;205=15 ~ 8;206=15 ~ 9;207=15 ~ 10;208=15 ~ 11;209=16;210=16 ~ 0;211=16 ~ 1;212=16 ~ 2;213=16 ~ 3;214=16 ~ 4;215=16 ~ 5;216=16 ~ 6;217=16 ~ 7;218=16 ~ 8;219=16 ~ 9;220=16 ~ 10;221=16 ~ 11;222=17;223=17 ~ 0;224=17 ~ 1;225=17 ~ 2;226=17 ~ 3;227=17 ~ 4;228=17 ~ 5;229=17 ~ 6;230=17 ~ 7;231=17 ~ 8;232=17 ~ 9;233=17 ~ 10;234=17 ~ 11;235=18;236=18 ~ 0;237=18 ~ 1;238=18 ~ 2;239=18 ~ 3;240=18 ~ 4;241=18 ~ 5;242=18 ~ 6;243=18 ~ 7;244=18 ~ 8;245=18 ~ 9;246=18 ~ 10;247=18 ~ 11;248=19;249=19 ~ 0;250=19 ~ 1;251=19 ~ 2;252=19 ~ 3;253=19 ~ 4;254=19 ~ 5;255=19 ~ 6;256=19 ~ 7;257=19 ~ 8;258=19 ~ 9;259=19 ~ 10;260=19 ~ 11;261=20+;262=20+ ~ N/A BHR_LONGITUDINAL_QUESTIONNAIRE Brain Health Registry LONGITUDINAL QUESTIONNAIRE
RID N/A N/A N/A UCSFATRPHY UCSF (Colin Studholme) Regional Atrophy Rates
RID Participant roster ID -4 N/A BHR_LONGITUDINAL_QUESTIONNAIRE Brain Health Registry LONGITUDINAL QUESTIONNAIRE
RID Participant roster ID N/A N/A UCSFFSL51ALL Longitudinal FreeSurfer (5.1) - All Available Base Image
RID Participant roster ID N/A N/A UCSFFSL51Y1 Longitudinal FreeSurfer (5.1) - Year 1 Base Image
RID Participant roster ID N/A N/A UCSFFSL51 Longitudinal FreeSurfer (5.1) - Final Run w/ All A
RID Participant roster ID N/A N/A UCSFFSL Longitudinal FreeSurfer (FreeSurfer Version 4.4)
RID Participant roster ID N/A N/A UCSFFSX51_ADNI1_3T ADNI-1 3T Cross-Sectional FreeSurfer (5.1)
RID Participant roster ID N/A N/A UCSFFSX51 Cross-Sectional FreeSurfer (5.1)
RID Participant roster ID N/A N/A UCSFFSX6 Cross-Sectional FreeSurfer (6.0)
RID Participant roster ID N/A N/A UCSFFSX Cross-Sectional FreeSurfer (FreeSurfer Version 4.3)
RID N/A N/A N/A UCSFSNTVOL UCSF SNT Hippocampal Volumes
RID Participant roster ID -4 N/A BHR_EVERYDAY_COGNITION Brain Health Registry EVERYDAY COGNITION
RID Participant roster ID -4 N/A UGOTPTAU181 University of Gothenburg Longitudinal plasma P-tau181
RID Participant roster ID -4 N/A UPENNBIOMK10 UPENN CSF Biomarkers Elecsys [ADNI3, batch I]
RID Participant roster ID N/A N/A UPENNBIOMK12_2020 UPENN CSF Biomarkers Elecsys
RID -4 -4 N/A UPENNBIOMK2 UPENN Longitudinal Biomarker Data
RID -4 -4 N/A UPENNBIOMK3 UPENN Longitudinal Biomarker Data (3 yr)
RID Participant roster ID -4 N/A BHR_BASELINE_QUESTIONNAIRE Brain Health Registry BASELINE QUESTIONNAIRE
RID RID -4 N/A UPENNBIOMK4 UPENN Longitudinal Biomarker Data (4 yr)
RID Participant roster ID -4 N/A UPENNBIOMK5 ADNI GO and ADNI 2: first batch analysis of CSF biomarkers
RID Participant roster ID -4 N/A UPENNBIOMK6 ADNI 2: second batch analysis of CSF biomarkers
RID Participant roster ID -4 N/A UPENNBIOMK7 UPENN-Third batch analysis of CSF biomarkers
RID Participant roster ID -4 N/A UPENNBIOMK8 UPENN - Fourth Batch Analyses of CSF Biomarkers
RID Participant roster ID -4 N/A UPENNBIOMK_ADNIDIAN_ES_2017 UPENN - ADNI/DIAN study CSF Elecsys results
RID Participant roster ID N/A N/A UPENNBIOMK_MASTER UPENN CSF Biomarkers
RID Participant roster ID -4 N/A UPENNMSMSABETA2CRM -4
RID Participant roster ID -4 N/A UPENNMSMSABETA2 -4
RID Participant roster ID -4 N/A UPENNMSMSABETA -4
RID Patient number N/A N/A UPENNPLASMA UPENN Plasma Biomarker Data
RID Participant roster ID -4 N/A UPENN_ROI_MARS UPENN - Hierarchical Parcellation of MRI Using Multi-atlas Labeling Methods
RID Participant roster ID -4 N/A UPENNSBIAROI University of Pennsylvania Section of Biomedical Image Analysis (SBIA) Volumes
RID Participant roster ID -4 N/A UPENNSPARE_AD Spatial Pattern of Abnormalities for Recognition of Early AD (SPARE-AD). C. Davatzikos. U. Penn.
RID Participant roster ID -4 N/A UPENNSPARE_MCI Spatial Pattern of Abnormalities for Recognition of Early MCI to AD conversion (SPARE-MCI). C. Davatzikos. U. Penn.
RID Participant roster ID -4 N/A UUCACIR UU PET Analysis
RID Participant roster ID -4 N/A UWNPSYCHSUM Crane Lab (UW) Neuropsych Summary Scores
RID Participant roster ID -4 N/A UWPLASMAEVAPOGEE University of Washington - Plasma EV Apogee
RID Participant roster ID -4 N/A ZHANG CSF Hemoglobin ELISA and PS129 Luminex Assays (Zhang Lab, University of Washington)
RID Participant roster ID -4 N/A ADMCBAPP AD Metabolomics Consortium Bile Acids - Post-processed
Visit_ID Visit ID for the subjects. Used along with RID to merge data with clinical variables N/A N/A ADMCBAPP AD Metabolomics Consortium Bile Acids
RID Participant roster ID -4 N/A UCBERKELEYAV45_8MM UC Berkeley - AV45 analysis
RID Participant roster ID N/A N/A UCSFASLFS ASL Perfusion CBF by FreeSurfer ROI
QID16_6 Are you currently taking any of the following medications? (Select all that apply)... Risperidone (Risperdal) 1=Yes;=No N/A BHR_BASELINE_QUESTIONNAIRE Brain Health Registry BASELINE QUESTIONNAIRE
QID16_7 Are you currently taking any of the following medications? (Select all that apply)... Paliperidone (Invega) 1=Yes;=No N/A BHR_BASELINE_QUESTIONNAIRE Brain Health Registry BASELINE QUESTIONNAIRE
QID19_6 Are you currently taking any of the following medications? (Select all that apply)... Risperidone (Risperdal) 1=Yes;=No N/A BHR_LONGITUDINAL_QUESTIONNAIRE Brain Health Registry LONGITUDINAL QUESTIONNAIRE
QID19_7 Are you currently taking any of the following medications? (Select all that apply)... Paliperidone (Invega) 1=Yes;=No N/A BHR_LONGITUDINAL_QUESTIONNAIRE Brain Health Registry LONGITUDINAL QUESTIONNAIRE
RID Participant roster ID N/A N/A ADNI_DIAN_COMPARISON The DIAN-ADNI Comparison Study
RID Participant roster ID -4 N/A SPAP_AVID_FLORBETAPIR sPAP Avid ADNI Florbetapir summaries
RID Participant roster ID -4 N/A ADSP_PHC_COGN ADSP Phenotype Harmonization Consortium (PHC) - Composite Cognitive Scores
RID Participant roster ID -4 N/A MAYOADIRL_MRI_FMRI Jack Lab - Default Mode Network connectivity
RID Participant roster ID The 4 digit roster ID (RID) should be used to merge data N/A N/A MAYOADIRL_MRI_FMRI_NFQ Jack Lab - fMRI Network Failure Quotient (NFQ)
RID Participant roster ID -4 N/A MAYOADIRL_MRI_IMAGEQC Jack Lab - ADNI GO/2 MRI QC
RID The 4 digit roster ID (RID) should be used to merge data N/A N/A MAYOADIRL_MRI_MCH Jack Lab - ADNI MRI MCH
RID Participant roster ID The 4 digit roster ID (RID) should be used to merge data N/A N/A MAYOADIRL_MRI_TBMSYN Jack Lab - TBM-SyN Based Scores
RID Participant roster ID N/A N/A UCSFASLFSCBF ASL Perfusion CBF by FreeSurfer ROI
RID Participant roster ID ADNI code N/A UCD_ADNI2_WMH Univerity of California Davis White Matter Hyperintensity Volumes (ADNI2)
RID Participant roster ID -4 N/A UCD_WMH UCD - White Matter Hyperintensity Volumes
RID Participant roster ID -4 N/A MAYOADIRL_MRI_ADNI3 Jack Lab - ADNI GO/2/3 MRI QC
AboutRID Participant roster ID -4 N/A BHR_SP_STUDY_CONFIRMATION Brain Health Registry SP STUDY CONFIRMATION
AboutRID Participant roster ID -4 N/A BHR_SP_RELATIONSHIP Brain Health Registry SP RELATIONSHIP
AboutRID Participant roster ID -4 N/A BHR_SP_INITIAL Brain Health Registry SP INITIAL
AboutRID Participant roster ID -4 N/A BHR_SP_FAQ Brain Health Registry SP FAQ
AboutRID Participant roster ID -4 N/A BHR_SP_EVERYDAY_COGNITION Brain Health Registry SP EVERYDAY COGNITION
AboutRID Participant roster ID -4 N/A BHR_SP_CAREGIVER_BURDEN Brain Health Registry SP CAREGIVER BURDEN
AboutRID Participant roster ID -4 N/A BHR_SP_ADL Brain Health Registry SP ADL
RID Participant roster ID N/A N/A APOEGO2 ADNI GO & 2 APOE Genotypes
USERID N/A N/A N/A APOEGO2 ADNI GO & 2 APOE Genotypes
USERID2 N/A N/A N/A APOEGO2 ADNI GO & 2 APOE Genotypes
RID Participant roster ID -4 N/A ADSP_PHC_BIOMARKER ADSP Phenotype Harmonization Consortium (PHC) - Composite Biomarker Scores
RID Participant roster ID -4 N/A FUJIREBIOABETAPLASMA Plasma Amyloid Beta (1-42/1-40) Ratio Biomarker Feasibility Study - Fujirebio Lumipulse
RID ADNI ID N/A N/A UPENNMIRNA UPENN CSF Plasma miRNA Data
RID Participant roster ID N/A N/A UPENNBIOMK_MASTER_OLD UPENN CSF Biomarker Master
RID Participant roster ID. NOTE: 9999999 denotes pooled sample. -4 N/A ADMC_DUKE_Q500_UPLC ADMC Duke Biocrates MxP Quant 500 Ultra Performance Liquid Chromatography Longitudinal ADNI -1, -GO, -2
DG(14:0_14:0) Diacylglyceride(14:0_14:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(14:0_18:1) Diacylglyceride(14:0_18:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(14:0_18:2) Diacylglyceride(14:0_18:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(14:0_20:0) Diacylglyceride(14:0_20:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(14:1_18:1) Diacylglyceride(14:1_18:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(14:1_20:2) Diacylglyceride(14:1_20:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(16:0_16:0) Diacylglyceride(16:0_16:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(16:0_16:1) Diacylglyceride(16:0_16:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(16:0_18:1) Diacylglyceride(16:0_18:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(16:0_18:2) Diacylglyceride(16:0_18:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(16:0_20:0) Diacylglyceride(16:0_20:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(16:0_20:3) Diacylglyceride(16:0_20:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(16:0_20:4) Diacylglyceride(16:0_20:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(16:1_18:0) Diacylglyceride(16:1_18:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(16:1_18:1) Diacylglyceride(16:1_18:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(16:1_18:2) Diacylglyceride(16:1_18:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(17:0_17:1) Diacylglyceride(17:0_17:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(17:0_18:1) Diacylglyceride(17:0_18:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(18:0_20:4) Diacylglyceride(18:0_20:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(18:1_18:1) Diacylglyceride(18:1_18:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(18:1_18:2) Diacylglyceride(18:1_18:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(18:1_18:3) Diacylglyceride(18:1_18:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(18:1_18:4) Diacylglyceride(18:1_18:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(18:1_20:1) Diacylglyceride(18:1_20:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(18:1_20:2) Diacylglyceride(18:1_20:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(18:1_20:3) Diacylglyceride(18:1_20:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(18:1_20:4) Diacylglyceride(18:1_20:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(18:1_22:5) Diacylglyceride(18:1_22:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(18:1_22:6) Diacylglyceride(18:1_22:6) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(18:2_18:2) Diacylglyceride(18:2_18:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(18:2_18:3) Diacylglyceride(18:2_18:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(18:2_18:4) Diacylglyceride(18:2_18:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(18:2_20:0) Diacylglyceride(18:2_20:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(18:2_20:4) Diacylglyceride(18:2_20:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(18:3_18:3) Diacylglyceride(18:3_18:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(18:3_20:2) Diacylglyceride(18:3_20:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(21:0_22:6) Diacylglyceride(21:0_22:6) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG(22:1_22:2) Diacylglyceride(22:1_22:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG-O(14:0_18:2) Diacylglyceride O-(14:0_18:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG-O(16:0_20:4) Diacylglyceride O-(16:0_20:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
DG-O(18:2_18:2) Diacylglyceride O-(18:2_18:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
RID Participant roster ID. NOTE: 9999999 denotes pooled sample. -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(14:0_32:2) Triacylglyceride(14:0_32:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(14:0_34:0) Triacylglyceride(14:0_34:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(14:0_34:1) Triacylglyceride(14:0_34:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(14:0_34:2) Triacylglyceride(14:0_34:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(14:0_34:3) Triacylglyceride(14:0_34:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(14:0_35:1) Triacylglyceride(14:0_35:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(14:0_35:2) Triacylglyceride(14:0_35:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(14:0_36:1) Triacylglyceride(14:0_36:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(14:0_36:2) Triacylglyceride(14:0_36:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(14:0_36:3) Triacylglyceride(14:0_36:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(14:0_36:4) Triacylglyceride(14:0_36:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(14:0_38:4) Triacylglyceride(14:0_38:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(14:0_38:5) Triacylglyceride(14:0_38:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(14:0_40:5) Triacylglyceride(14:0_40:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_28:1) Triacylglyceride(16:0_28:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_28:2) Triacylglyceride(16:0_28:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_30:2) Triacylglyceride(16:0_30:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_32:0) Triacylglyceride(16:0_32:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_32:1) Triacylglyceride(16:0_32:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_32:2) Triacylglyceride(16:0_32:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_32:3) Triacylglyceride(16:0_32:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_33:1) Triacylglyceride(16:0_33:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_33:2) Triacylglyceride(16:0_33:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_34:0) Triacylglyceride(16:0_34:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_34:1) Triacylglyceride(16:0_34:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_34:2) Triacylglyceride(16:0_34:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_34:3) Triacylglyceride(16:0_34:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_34:4) Triacylglyceride(16:0_34:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_35:1) Triacylglyceride(16:0_35:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_35:2) Triacylglyceride(16:0_35:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_35:3) Triacylglyceride(16:0_35:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_36:2) Triacylglyceride(16:0_36:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_36:3) Triacylglyceride(16:0_36:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_36:4) Triacylglyceride(16:0_36:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_36:5) Triacylglyceride(16:0_36:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_36:6) Triacylglyceride(16:0_36:6) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_37:3) Triacylglyceride(16:0_37:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_38:1) Triacylglyceride(16:0_38:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_38:2) Triacylglyceride(16:0_38:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_38:3) Triacylglyceride(16:0_38:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_38:4) Triacylglyceride(16:0_38:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_38:5) Triacylglyceride(16:0_38:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_38:6) Triacylglyceride(16:0_38:6) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_38:7) Triacylglyceride(16:0_38:7) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_40:6) Triacylglyceride(16:0_40:6) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_40:7) Triacylglyceride(16:0_40:7) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:0_40:8) Triacylglyceride(16:0_40:8) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:1_28:0) Triacylglyceride(16:1_28:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:1_30:1) Triacylglyceride(16:1_30:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:1_32:0) Triacylglyceride(16:1_32:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:1_32:1) Triacylglyceride(16:1_32:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:1_32:2) Triacylglyceride(16:1_32:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:1_33:1) Triacylglyceride(16:1_33:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:1_34:0) Triacylglyceride(16:1_34:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:1_34:1) Triacylglyceride(16:1_34:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:1_34:2) Triacylglyceride(16:1_34:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:1_34:3) Triacylglyceride(16:1_34:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:1_36:1) Triacylglyceride(16:1_36:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:1_36:2) Triacylglyceride(16:1_36:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:1_36:3) Triacylglyceride(16:1_36:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:1_36:4) Triacylglyceride(16:1_36:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:1_36:5) Triacylglyceride(16:1_36:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:1_38:3) Triacylglyceride(16:1_38:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:1_38:4) Triacylglyceride(16:1_38:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(16:1_38:5) Triacylglyceride(16:1_38:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:0_32:1) Triacylglyceride(17:0_32:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:0_34:1) Triacylglyceride(17:0_34:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:0_34:2) Triacylglyceride(17:0_34:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:0_34:3) Triacylglyceride(17:0_34:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:0_36:3) Triacylglyceride(17:0_36:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:0_36:4) Triacylglyceride(17:0_36:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:1_32:1) Triacylglyceride(17:1_32:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:1_34:1) Triacylglyceride(17:1_34:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:1_34:2) Triacylglyceride(17:1_34:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:1_34:3) Triacylglyceride(17:1_34:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:1_36:3) Triacylglyceride(17:1_36:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:1_36:4) Triacylglyceride(17:1_36:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:1_36:5) Triacylglyceride(17:1_36:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:1_38:5) Triacylglyceride(17:1_38:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:1_38:6) Triacylglyceride(17:1_38:6) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:1_38:7) Triacylglyceride(17:1_38:7) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:2_34:2) Triacylglyceride(17:2_34:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:2_34:3) Triacylglyceride(17:2_34:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:2_36:2) Triacylglyceride(17:2_36:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:2_36:3) Triacylglyceride(17:2_36:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:2_36:4) Triacylglyceride(17:2_36:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:2_38:5) Triacylglyceride(17:2_38:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:2_38:6) Triacylglyceride(17:2_38:6) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(17:2_38:7) Triacylglyceride(17:2_38:7) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:0_30:0) Triacylglyceride(18:0_30:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:0_30:1) Triacylglyceride(18:0_30:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:0_32:0) Triacylglyceride(18:0_32:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:0_32:1) Triacylglyceride(18:0_32:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:0_32:2) Triacylglyceride(18:0_32:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:0_34:2) Triacylglyceride(18:0_34:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:0_34:3) Triacylglyceride(18:0_34:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:0_36:1) Triacylglyceride(18:0_36:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:0_36:2) Triacylglyceride(18:0_36:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:0_36:3) Triacylglyceride(18:0_36:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:0_36:4) Triacylglyceride(18:0_36:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:0_36:5) Triacylglyceride(18:0_36:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:0_38:6) Triacylglyceride(18:0_38:6) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:0_38:7) Triacylglyceride(18:0_38:7) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_26:0) Triacylglyceride(18:1_26:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_28:1) Triacylglyceride(18:1_28:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_30:0) Triacylglyceride(18:1_30:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_30:1) Triacylglyceride(18:1_30:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_30:2) Triacylglyceride(18:1_30:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_31:0) Triacylglyceride(18:1_31:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_32:0) Triacylglyceride(18:1_32:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_32:1) Triacylglyceride(18:1_32:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_32:2) Triacylglyceride(18:1_32:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_32:3) Triacylglyceride(18:1_32:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_33:0) Triacylglyceride(18:1_33:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_33:1) Triacylglyceride(18:1_33:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_33:2) Triacylglyceride(18:1_33:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_33:3) Triacylglyceride(18:1_33:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_34:1) Triacylglyceride(18:1_34:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_34:2) Triacylglyceride(18:1_34:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_34:3) Triacylglyceride(18:1_34:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_34:4) Triacylglyceride(18:1_34:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_35:2) Triacylglyceride(18:1_35:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_35:3) Triacylglyceride(18:1_35:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_36:0) Triacylglyceride(18:1_36:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_36:1) Triacylglyceride(18:1_36:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_36:2) Triacylglyceride(18:1_36:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_36:3) Triacylglyceride(18:1_36:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_36:4) Triacylglyceride(18:1_36:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_36:5) Triacylglyceride(18:1_36:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_36:6) Triacylglyceride(18:1_36:6) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_38:5) Triacylglyceride(18:1_38:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_38:6) Triacylglyceride(18:1_38:6) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:1_38:7) Triacylglyceride(18:1_38:7) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_28:0) Triacylglyceride(18:2_28:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_30:0) Triacylglyceride(18:2_30:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_30:1) Triacylglyceride(18:2_30:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_31:0) Triacylglyceride(18:2_31:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_32:0) Triacylglyceride(18:2_32:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_32:1) Triacylglyceride(18:2_32:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_32:2) Triacylglyceride(18:2_32:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_33:0) Triacylglyceride(18:2_33:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_33:1) Triacylglyceride(18:2_33:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_33:2) Triacylglyceride(18:2_33:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_34:0) Triacylglyceride(18:2_34:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_34:1) Triacylglyceride(18:2_34:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_34:2) Triacylglyceride(18:2_34:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_34:3) Triacylglyceride(18:2_34:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_34:4) Triacylglyceride(18:2_34:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_35:1) Triacylglyceride(18:2_35:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_35:2) Triacylglyceride(18:2_35:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_35:3) Triacylglyceride(18:2_35:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_36:0) Triacylglyceride(18:2_36:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_36:1) Triacylglyceride(18:2_36:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_36:2) Triacylglyceride(18:2_36:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_36:3) Triacylglyceride(18:2_36:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_36:4) Triacylglyceride(18:2_36:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_36:5) Triacylglyceride(18:2_36:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_38:4) Triacylglyceride(18:2_38:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_38:5) Triacylglyceride(18:2_38:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:2_38:6) Triacylglyceride(18:2_38:6) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:3_30:0) Triacylglyceride(18:3_30:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:3_32:0) Triacylglyceride(18:3_32:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:3_32:1) Triacylglyceride(18:3_32:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:3_33:2) Triacylglyceride(18:3_33:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:3_34:0) Triacylglyceride(18:3_34:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:3_34:1) Triacylglyceride(18:3_34:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:3_34:2) Triacylglyceride(18:3_34:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:3_34:3) Triacylglyceride(18:3_34:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:3_35:2) Triacylglyceride(18:3_35:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:3_36:1) Triacylglyceride(18:3_36:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:3_36:2) Triacylglyceride(18:3_36:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:3_36:3) Triacylglyceride(18:3_36:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:3_36:4) Triacylglyceride(18:3_36:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:3_38:5) Triacylglyceride(18:3_38:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(18:3_38:6) Triacylglyceride(18:3_38:6) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:0_32:3) Triacylglyceride(20:0_32:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:0_32:4) Triacylglyceride(20:0_32:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:0_34:1) Triacylglyceride(20:0_34:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:1_24:3) Triacylglyceride(20:1_24:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:1_26:1) Triacylglyceride(20:1_26:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:1_30:1) Triacylglyceride(20:1_30:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:1_32:0) Triacylglyceride(20:1_32:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:1_32:1) Triacylglyceride(20:1_32:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:1_32:2) Triacylglyceride(20:1_32:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:1_32:3) Triacylglyceride(20:1_32:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:1_34:0) Triacylglyceride(20:1_34:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:1_34:1) Triacylglyceride(20:1_34:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:1_34:2) Triacylglyceride(20:1_34:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:1_34:3) Triacylglyceride(20:1_34:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:2_32:0) Triacylglyceride(20:2_32:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:2_32:1) Triacylglyceride(20:2_32:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:2_34:1) Triacylglyceride(20:2_34:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:2_34:2) Triacylglyceride(20:2_34:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:2_34:3) Triacylglyceride(20:2_34:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:2_34:4) Triacylglyceride(20:2_34:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:2_36:5) Triacylglyceride(20:2_36:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:3_32:0) Triacylglyceride(20:3_32:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:3_32:1) Triacylglyceride(20:3_32:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:3_32:2) Triacylglyceride(20:3_32:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:3_34:0) Triacylglyceride(20:3_34:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:3_34:1) Triacylglyceride(20:3_34:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:3_34:2) Triacylglyceride(20:3_34:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:3_34:3) Triacylglyceride(20:3_34:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:3_36:3) Triacylglyceride(20:3_36:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:3_36:4) Triacylglyceride(20:3_36:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:3_36:5) Triacylglyceride(20:3_36:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:4_30:0) Triacylglyceride(20:4_30:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:4_32:0) Triacylglyceride(20:4_32:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:4_32:1) Triacylglyceride(20:4_32:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:4_32:2) Triacylglyceride(20:4_32:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:4_33:2) Triacylglyceride(20:4_33:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:4_34:0) Triacylglyceride(20:4_34:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:4_34:1) Triacylglyceride(20:4_34:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:4_34:2) Triacylglyceride(20:4_34:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:4_34:3) Triacylglyceride(20:4_34:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:4_35:3) Triacylglyceride(20:4_35:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:4_36:2) Triacylglyceride(20:4_36:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:4_36:3) Triacylglyceride(20:4_36:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:4_36:4) Triacylglyceride(20:4_36:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:4_36:5) Triacylglyceride(20:4_36:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:5_34:0) Triacylglyceride(20:5_34:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:5_34:1) Triacylglyceride(20:5_34:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:5_34:2) Triacylglyceride(20:5_34:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:5_36:2) Triacylglyceride(20:5_36:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(20:5_36:3) Triacylglyceride(20:5_36:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(22:0_32:4) Triacylglyceride(22:0_32:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(22:1_32:5) Triacylglyceride(22:1_32:5) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(22:2_32:4) Triacylglyceride(22:2_32:4) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(22:3_30:2) Triacylglyceride(22:3_30:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(22:4_32:0) Triacylglyceride(22:4_32:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(22:4_32:2) Triacylglyceride(22:4_32:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(22:4_34:2) Triacylglyceride(22:4_34:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(22:5_32:0) Triacylglyceride(22:5_32:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(22:5_32:1) Triacylglyceride(22:5_32:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(22:5_34:1) Triacylglyceride(22:5_34:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(22:5_34:2) Triacylglyceride(22:5_34:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(22:5_34:3) Triacylglyceride(22:5_34:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(22:6_32:0) Triacylglyceride(22:6_32:0) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(22:6_32:1) Triacylglyceride(22:6_32:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(22:6_34:1) Triacylglyceride(22:6_34:1) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(22:6_34:2) Triacylglyceride(22:6_34:2) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
TG(22:6_34:3) Triacylglyceride(22:6_34:3) -4 N/A ADMC_DUKE_Q500_FIA ADMC Duke Biocrates MxP Quant 500 Flow injection analysis Longitudinal ADNI-1, -GO, -2
PTID ADNI Participant ID consisting of 3-digit "SITEID" and 4-digit "RID" N/A N/A UCBERKELEY_AMY_6MM UC Berkeley - Amyloid PET 6mm Res analysis
RID Participant roster ID (unique participant identifier that should be used to merge data) N/A N/A UCBERKELEY_AMY_6MM UC Berkeley - Amyloid PET 6mm Res analysis
PTID ADNI Participant ID consisting of 3-digit "SITEID" and 4-digit "RID" N/A N/A UCBERKELEY_TAU_6MM UC Berkeley - Tau PET 6mm Res analysis
RID Participant roster ID (unique participant identifier that should be used to merge data) N/A N/A UCBERKELEY_TAU_6MM UC Berkeley - Tau PET 6mm Res analysis
RID Participant roster ID -4 N/A ADNI3_URMC_LABDATA ADNI3 URMC Lab Data
RID Participant ID N/A N/A ADSP_PHC_ADNI_T1_1.0_MetaData ADNI Meta Data for U24 Phase 1 T1 Release
RID Patient ID N/A N/A SELKOELAB_NT1TAU Plasma NT1-tau in ADNI